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Mrs. X. is a 88 year old women who has been referred to our falls and syncope 
outpatient department because of a recent fall, probably with syncope, and a 
history of recurrent falls. Mrs. X. has a medical history of Alzheimer’s dementia 
(AD), obesity, hypertension, osteoporosis, osteo-arthritis and myocardial 
infarction for which she uses eight different medications, including a 
cholinesterase inhibitor for AD. She quitted smoking after her myocardial 
infarction approximately 10 years ago and consumed alcohol sporadically. Mrs. 
X. has worked as a kindergarten teacher, before she got married with her 
husband and has three children. After the children left the house she worked as 
a secretary in a great company. Her children live at a large distance, but the 
relation with them is good. She and her 91 year old husband live independently 
with a little help from their neighbors and children.  
 Because of her AD she cannot tell exactly what happened when she lastly 
fell. Her 91 year old husband found her three times lying on the ground calling 
for help in the past six months. He witnessed only one fall. He described that she 
lost her consciousness after standing up from the dining table, where they had 
enjoyed diner half an hour earlier, and walked to the kitchen to put a carafe 
above the sink. After she fell, she regained consciousness very quickly in less 
than a minute. Luckily she did not hurt herself and recognized her husband 
immediately. Her husband did not notice any particularities during syncope. 
Afterwards there were no specific complaints.  
 Besides a standard comprehensive geriatric assessment, she underwent a 
SMC-test (Stand, Meal and Carotid sinus massage) protocol in the morning, 
after an overnight fast, including abstaining from her morning medication. This 
test is meant to detect orthostatic hypotension (OH), postprandial hypotension 
(PPH) and carotid sinus hypersensitivity (CSH), respectively. During the 
SMC-test the blood pressure (BP) was measured continuously, non-invasively 
with the Finometer (Finapres Medical Systems, Amsterdam, the Netherlands). 
Heart rate was recorded with a double lead ECG. Upon standing (Stand test) her 
BP dropped from a baseline BP of 170/85 mmHg after 10 minutes of supine rest 
to a minimum of 130/60 mmHg in the first 15 seconds. She was asymptomatic 
and BP recovered very quickly to 180/85 mmHg after 1 minute of standing. 
Hereafter a minimum of BP of 140/60 mmHg was reached after approximately 2 
minutes of standing. At this time, she complained of transient fatigue and light-
headedness. She could not recollect if she experienced the same complaints 
when she fell at home. After eating a standardized meal (Meal-test), BP dropped 
from the baseline BP of 170/85 mmHg to a minimum of 145/75 mmHg after 30 
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minutes without experiencing complaints. Lastly, carotid sinus massage was 
performed in the supine position. On the right side, BP decreased from the 
baseline BP of 170/85 mmHg to 125/65 with a maximum R-R interval of 2.2 
seconds. On the lift side, BP decreased to 130/60 with a maximum R-R interval 
of 3.1 seconds. During both carotid sinus massages, she remained asymptomatic. 
 In summary, these observations during blood pressure stress tests showed 
that Mrs. X. had symptomatic OH, asymptomatic PPH and asymptomatic CSH, 
without showing evidence for syncope (for criteria of OH, PPH, and CSH, see 
below). Mrs. X. illustrates a typical, average patient seen on our falls and syncope 
outpatient clinic and her case illustrates the complex nature of falls and syncope 
in the elderly. This case raises several questions which form the basis of this thesis. 
 First, in Mrs. X. three geriatric hypotensive syndromes (OH, PPH, and CSH) 
occur together. Is this by chance, because these three hypotensive syndromes 
are common in old age, or do these three syndromes share a common patho-
physiology? Second, do these syndromes predict mortality? Is the occurrence of 
these hypotensive syndromes in Mrs. X. an indicator for a shorter life expectancy? 
Third, in line with the second question, does a large BP decrease immediately 
after standing, but also the amount of recovery afterwards, predict mortality? 
Fourth, is Mrs. X. prone to these BP regulation disorders, because of her neuro-
degenerative AD, which might affect central BP regulation mechanisms? Have 
patients with AD worse BP regulation? Does her cholinesterase inhibitor use 
influences BP regulation? Finally, it is very relevant in case of Mrs. X. to know 
whether she is at high risk for more symptoms of hypoperfusion of the brain due 
to her AD, because of a possibly affected cerebral autoregulation with AD? As 
such, the final question is whether AD-patients on average have impaired 
cerebral autoregulation?   
   
Background
Before discussing these research questions in more detail, some background 
information on BP regulation and cerebral autoregulation is provided below. 
Cerebral blood flow is maintained stable through combined effects of BP 
regulation and cerebral autoregulation.(1-3) 
Blood pressure regulation
Arterial BP is determined by cardiac output and peripheral resistance. Cardiac 
output is the result of heart rate and stroke volume. Stroke volume is related to 
myocardial contractility and the size of the vascular compartment (intravascular 
blood volume, Frank-Starling law).(4) Peripheral resistance is determined by 
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the structure and function of small arteries and arterioles.(5,6) Although the 
regulation of arterial BP is not fully understood, the following mechanisms play 
a role in BP regulation.(4,6-8) 
1) Neural regulation by the autonomic nervous system
The central autonomic nervous system receives BP information from 
baroreceptors (and other receptors, like chemoreceptors), and controls BP to 
keep fluctuations small through the baroreflex.(4,6) The baroreflex is a reflex 
loop with cardiac, vascular, and cerebral components involved in short-term BP 
regulation.(9,10) The arterial baroreflex is induced by nerve receptors called 
baroreceptors, which are located mainly in the walls of the aorta in the chest and 
the walls of the internal carotid arteries in the neck.(8) These receptors are 
stimulated when increased pressure stretches the vessel walls.(10) The receptors 
send signals to the cardiovascular control center in the medulla oblongata.(6,10) 
From here afferent nerves run to atria, ventricles, arteries, arterioles, venules, 
veins and adrenal glands.(6) The baroreflex operates via the autonomic nervous 
system to restore sudden changes in BP by changing heart rate or vascular tone. 
A clinical example is the drop in BP upon standing, which the baroreflex corrects 
by a rapid increase in heart rate (parasympathetic inhibition) followed by 
peripheral arterial vasoconstriction and increased cardiac contractility (sympathetic 
activation).(10) The parasympathethic system operates faster than the sympathetic 
system. Heart rate changes mediated by signals though the vagal nerve have a 
latency of about 0.5 seconds and a time constant of a few seconds, whereas these 
values are 1-3 seconds and 10 seconds respectively for the sympathicus.(11) This 
baroreflex is impaired with advancing age(1,9,10,12,13) and increasing BP levels.
(9,10,12). Endurance training improves cardiac baroreflex function.(1,14). 
Remarkably, there still is a paucity of data on the baroreflex function in patients 
with AD and on the effects of drug application in AD.(15) The main neurotrans-
mitter for the parasympathetic autonomic system is acetylcholine. Theoretically, 
the use of an acethylcholinesterase inhibitor might improve baroreflex function. 
Prospective data collection on these issues is still required, for safe and evidence 
based prescription of acetylcholinesterase inhibitors.
2) Humoral regulation
The best known hormonal system to regulate BP is the Renin-Angiotensin-Aldo-
sterone-System (RAAS).(4) The RAAS is activated when low BP causes the blood 
flow through the kidneys to fall below normal. The low flow makes the kidneys 
secrete renin into the blood and splits angiotensin I from angiotensinogen. 
Angiotensin I is converted to Angiotensin II by angiotensin-converting enzyme. 
Angiotensin II is the dominant effector molecule of the RAAS and constricts the 
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small arteries throughout the body and promotes renal tubular sodium and 
water retention, by secretion of aldosterone by the adrenal cortex.(7,8) The renin-
angiotensin vasoconstrictor mechanism operates in minutes.(8) Aldosterone has 
its BP regulating effects in hours. Besides the RAAS, other classical circulating 
hormones, like catecholamines and vasopressin also play a role in BP regulation. 
3) Renal volume regulation 
The kidneys importantly contribute to BP regulation by their key role in 
regulating body fluid volume through their water conservation and the opposing 
diuretic function.(4,6) When the arterial pressure rises above normal, the excess 
pressure causes the kidneys to excrete more water and salt than are entering the 
body. Therefore, the blood volume decreases. This causes the heart to pump less 
blood, and the arterial pressure to fall.(8) This kidney-fluid system is a slow 
acting regulator which exert its influence in days.(8) 
The different mechanisms are not working in isolation, there is considerable 
neuro-humoral interaction present.(4) For example, the kidneys are innervated 
by the sympathetic autonomic nervous system and vasopressin reduces the 
baroreceptor sensitivity.(4)  
Variability of heart rate and blood pressure
BP and heart rate continuously fluctuate over time, under the influence of the 
above mentioned control mechanisms, which together safeguard cardiovascular 
homeostasis.(16) Therefore, this variability directly reflects the activity of 
cardiovascular control mechanisms.(16) Consequently, heart rate variability 
(HRV) and blood pressure variability (BPV) are used to explore autonomic 
cardiovascular modulation. However, while HRV largely reflects selective 
autonomic control of the heart, BPV is the result of complex interactions between 
multiple mechanisms.(17) Nevertheless HRV or BPV can provide a valuable 
insight into integrated cardiovascular regulation.(17) The advantages of this 
approach are that it is easy applicability in daily practice and that it avoids any 
external intervention on subjects under evaluation.(16,17) HRV and BPV, but also 
the earlier mentioned baroreceptor sensitivity are established and frequently 
used measures of cardiovascular autonomic function in research.(10,18,19) In 
these thesis we will use several non-invasive indices of HRV, BPV and 
baroreceptor sensitivity to determine autonomic function and to study its role in 
hypotensive syndromes (see below). Although autonomic dysfunction plays a 
important role in specific diseases, such as multiple system atrophy, Parkinson’s 
disease, pure autonomic failure and diabetic and amyloid neuropathy(19,20), its 




OH, PPH and CSH are disorders of BP regulation with high prevalence in the 
elderly.(21-23) If the cerebral circulation becomes critically compromised by 
these hypotensive syndromes, susceptible individuals may experience 
weakness, fatigue, blurred vision, dizziness, pain in the neck and shoulders 
(‘coat hanger’ pain) and syncope.(3,24,25) Therefore, detection and management 
of these hypotensive syndromes is crucial in order to improve quality of life of 
patients, prevent syncopal attacks and fall-related injuries, and to optimize 
treatment of concomitant diseases, such as hypertension and heart failure.(20,24)
 OH is the best known hypotensive syndrome. OH is defined as a systolic 
blood pressure (SBP) decrease of 20 mmHg or more or to below 90 mmHg and/
or a diastolic blood pressure (DBP) decline of 10 mmHg or more between 1 and 
3 minutes after standing from supine.(24) Recently a new consensus on 
orthostatic intolerance syndromes has been reached(25), with a decrease in SBP 
of 30 mmHg of more suggested to be a more appropriate diagnostic limit among 
hypertensive patients (i.e. those with supine SBP of 160 mmHg or more). Besides 
“classical” OH, also an initial BP decrease directly after standing with subsequent 
recovery in the first minute can be distinguished.(26) This initial response can 
only be measured with continuous noninvasive monitoring.(25) The (patho-)
physiology of BP decline directly after standing is as follows. Moving from the 
supine to upright posture results in the translocation of 300-1000 mL of blood 
from the central intravascular compartment to dependent regions in the legs, 
buttocks, pelvis and splanchnic circulation.(19,20,25) As a result, the venous 
return to the right atrium and the thoracic blood and stroke volume are all 
reduced, and reflex chronotropic and vasoconstrictive responses mediated by 
increased sympathetic outflow and decreased vagal activity compensate to 
maintain arterial pressure in the upper body at the pre-orthostatic level, 
respectively.(20,25-27) If, one continues to stand, transcapillary filtration in the 
subdiaphragmatic space additionally reduces the central blood volume with 
about 15%(3,6,20,27), while the cardiac output decreases by nearly 20%.(20,27) 
In a healthy subject, however, mean arterial pressure is preserved, because of 
compensatory increases in vascular tone in splanchnic, musculocutaneous and 
renal areas.(3,20) The rapid circulatory adjustments are governed merely by 
autonomic neural pathways, whereas circulatory changes that occur during the 
prolonged orthostatic challenge involve neurohumoral mechanisms, such as 
activation of the renin-angiotensin system(3,20). 
 PPH is defined as a SBP decline of 20 mmHg or more within 75 minutes after 
a meal.(28,29) PPH appears to result from inadequate compensation for the normal 
physiologic postmeal decrease in BP, rather than from an exaggerated amount of 
splanchnic pooling.(30) A blunted sympathetic response to hypotension appears 
14
CHAPTER 1
to be responsible for the compensatory failure that underlies PPH. A micro-
neurographic study of muscle sympathetic activity demonstrated that elders 
respond to an oral glucose load with a smaller increase in sympathetic activity, 
in comparison with younger subjects.(30,31) Stretch receptors in the stomach 
normally also can activate sympathetic signaling, by which gastric distention 
normally has a pressor effect. However, in the elderly, this “gastrovascular 
reflex” is blunted.(30,32) This statement is also supported by the observation that 
there is no difference in muscle sympathetic nerve activity between the healthy 
elderly and young patients in response to an intraduodenal glucose load.(30,33)
 CSH is defined as an interruption of heart rate over at least 3 seconds and/
or as a decrease of SBP of 50 mmHg or more after carotid sinus massage.(24) The 
pathophysiological processes underlying CSH remain poorly understood.(34) 
Perhaps CSH is associated with neurodegeneration and may be part of more 
widespread autonomic dysfunction, rather than a localized disorder within the 
carotid sinus.(34,35)
 In elderly patients 85 years of age or older, the association between BP and 
mortality or cardiovascular risk is absent or less strong than in younger patients.
(5,36) OH predicts mortality in middle-aged patients(37-39), however the 
association in elderly patients seems inconsistent.(40-43) The information on 
PPH or CSH and mortality is sparse.(28,29,44,45)
Cerebral autoregulation
Cerebral blood vessels have an inherent ability to keep cerebral blood flow 
constant in response to changes in arterial BP or intracranial pressure.(2) 
In response to a variation in perfusion pressure (mean arterial pressure – 
intracranial pressure), an adaptation in cerebrovascular resistance by means of 
myogenic, neurogenic or metabolic mechanisms will cause cerebral blood flow 
to return to its baseline.(2,46-48) This hemodynamic process is known as cerebral 
autoregulation.(2,46,47,49) The term autoregulation within the cerebral circulation 
was introduced by Lassen in 1959.(2,46) Lassen introduced the classic cerebral 
autoregulatory curve in which cerebral blood flow remains constant over a wide 
range of BP, the plateau phase, with the upper and lower limits forming the 
boundaries of cerebral autoregulation.(2,46,47) This curve reflects static cerebral 
autoregulation and is composed of several different studies that assess the 
semi-steady state reactions of cerebral blood flow on sustained periods of 
hypertension or hypotension by pharmacological interventions. However, the 
clinical applicability of this artificially created static cerebral autoregulation 
estimation is limited.(2) Technological developments as transcranial Doppler 
 ultrasonography(49,50) and servo-controlled finger photoplethysmography(51) 
(Finapres) have offered possibilities to investigate the dynamics of cerebral 
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autoregulation. In contrast to studies of the static cerebral autoregulation, 
dynamic studies of cerebral autoregulation quantify the fast modifications in 
cerebral blood flow velocity in a major cerebral artery in relation to rapid 
alterations in BP within the upper and lower limits of static cerebral 
autoregulation.(2) For studies of dynamic cerebral autoregulation, a pharmaco-
logical intervention is not required, and the method is entirely noninvasive, 
which makes it clinically suitable in frail older patients, even when they suffer 
from AD. However, these dynamic studies are not able to measure flow at the 
brain tissue level.(2) Additionally, noninvasive information of change of blood 
volume level in the brain tissue can be obtained with near infrared spectroscopy 
(NIRS).(52) The impact of AD on dynamic cerebral autoregulation is not well 
know, but is important to be studied to understand the variability in the 
presentation of symptoms in patients with geriatric orthostatic syndromes.(53) 
Aims 
Given the impact and high prevalence of hypotensive syndromes and AD, the 
relevance of the questions raised from daily clinical practice, and on the basis of 
lack of knowledge on these issues as described above, this thesis addresses three 
different but coherent questions related to BP and cerebral autoregulation. 
 First, we investigate evidence for a direct role of autonomic dysfunction in 
the etiology of geriatric hypotensive syndromes in falls patients, and whether 
these hypotensive syndromes share a common pathophysiology. With abundant 
evidence on the important role of autonomic dysfunction in syncope in younger 
patients, the role of autonomic dysfunction of geriatric hypotensive syndromes 
is unclear. 
 Second, we investigate the correlation of these hypotensive syndromes with 
mortality. Besides the relation of the different hypotensive syndromes with mortality, 
we also looked at the relationship with mortality of the amount of BP decline, and the 
ability of BP recovery. As pointed out above, the research on the association of OH, 
PPH and CSH and mortality in elderly patients is inconsistent or sparse. 
 Third, we examined the role of AD on BP regulation, through baroreflex 
functioning and the impact of AD on dynamic cerebral autoregulation. AD and 
cardiovascular disease share the same risk factors.(54) Vascular factors may 
partially cause or aggravate AD(54), but AD may also directly cause alterations 
of BP regulation and dynamic cerebral autoregulation by the neurodegenerative 
process in relevant brain centres and strongly related cerebral amyloid 
angiopathy. Hence, it’s also highly relevant to investigate the influence of AD on 
these regulatory mechanisms. 
16
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Outline of this thesis
Chapter 2a investigates the association between three hypotensive syndromes 
(OH, PPH and CSH) and several non-invasive autonomic function measures in a 
cross-sectional study of geriatric patients visiting our outpatient falls clinic. 
Chapter 2b is a letter to the editor in which some remarks are made by us about 
the relevance and shortcomings of a proposed monocausal diagnostic syncope 
test for a heterogenic geriatric falls population with multicausal etiology. 
Chapter 3a researches the possibly shared pathophysiology of three hypotensive 
syndromes (OH, PPH and CSH). Also the impact on mortality of these three 
syndromes is studied in a retrospective cohort study design of elderly patients 
visiting our outpatient falls clinic. Finally, the relation between the amount of 
BP decline during testing for the above mentioned hypotensive syndromes and 
mortality is investigated. Chapter 3b is a letter to the editor highlighting the 
rationale and relevance to perform our study. Chapter 3c is a letter to the editor 
questioning the role of DBP decline during OH in middle aged adults.  
Chapter 4 studies the association between the amount of BP decline directly 
after active standing and mortality in a retrospective design. The association 
with mortality was also investigated for the BP recovery after the initial BP 
decline. 
Chapter 5a investigates the baroreflex functioning in patients with AD, patients 
with mild cognitive impairment and healthy elderly. Also the influence of 
cholinesterase inhibitors on baroreceptor sensitivity is studied. Chapter 5b is a 
letter to the editor which discusses the potential additive role of BPV, above 
absolute BP, on cognitive decline in older people. This as an example of the 
complex reciprocal interaction of vascular factors and cognition.
Chapter 6 assesses the dynamic cerebral autoregulation in patients with AD 
and healthy elderly with transcranial Doppler and NIRS.
In Chapter 7 the preceding chapters are summarized and discussed in the light 
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Though highly prevalent, the pathophysiology of orthostatic hypotension (OH), 
postprandial hypotension (PPH), and carotid sinus hypersensitivity (CSH) are 
rarely studied together. Therefore we conducted such a comprehensive study 
focusing on the common role of the cardiovascular autonomic system. We 
hypothesized that in geriatric patients, OH, PPH and CSH are manifestations of 
cardiovascular autonomic dysfunction, and investigated state-of-the-art cardio-
vascular autonomic function indices in a group of geriatric falls or syncope 
patients.
Methods
In a cross-sectional study of 203 consecutive eligible falls clinic patients, we 
compared heart rate variability (HRV), blood pressure variability (BPV), and 
baroreflex sensitivity (BRS) as potential autonomic function determinants of the 
three different hypotensive syndromes. 
Results
OH, PPH, and CSH were diagnosed in 53%, 57%, and 50% of the patients, 
respectively. In a population relevant for geriatric practice, we found no 
differences in HRV, BPV, and BRS between patients with and without OH, with 
and without PPH and with and without CSH, respectively, nor between patients 
with and without falls, dizziness or syncope as presenting symptom, respectively.
Conclusions
In geriatric patients with hypotensive syndromes, cardiovascular autonomic 
function as measured by HRV, BPV, and BRS is comparable to patients without 
such syndromes. These findings argue against a single or dominant etiological 
factor, that is, cardiac autonomic dysfunction and underline the structured, 
broad and multifactorial approach to elderly patients with falls and/or syncope 
as proposed in the current evidence-based syncope guidelines. 
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Introduction 
Heart rate variability (HRV), blood pressure variability (BPV), and baroreceptor 
sensitivity (BRS) are established measures of cardiovascular autonomic function 
in research.(1-3) The clinical relevance of these measures has also been shown, 
as diminished BRS, diminished HRV, and increased BPV have prognostic 
significance for mortality and cardiovascular risk.(4-6) 
 Orthostatic hypotension (OH), postprandial hypotension (PPH), and carotid 
sinus hypersensitivity (CSH) are disorders of blood pressure (BP) regulation 
with high prevalence in the elderly patients.(7-12)  OH is predominantly seen as 
a disorder of autonomic failure, and PPH and CSH are classified as reflex or 
neurally mediated syncope.(13) The cardiovascular autonomic system plays an 
important role in the distribution of blood volume and the regulation of 
BP,(8;14-17) and failure of this system might play an important role in the etiology 
and pathophysiology of these hypotensive syndromes. 
 Therefore, we hypothesized that commonly available and non-invasive 
autonomic function indices of HRV, BPV and BRS are different in patients with 
and without OH, PPH, and CSH.
Methods
Study Population 
This study included 242 consecutive patients, who visited the geriatric outpatient 
falls and syncope clinic of the Radboud University Nijmegen Medical Centre 
because of falls, dizziness and/or syncope. This test protocol was part of the 
standard diagnostic work-up. Patients were excluded if they were unable to 
follow the instructions due to delirium, psychosis or very severe dementia 
(Clinical Dementia Rating 3), if they were unable to stand for 10 min or drink a 
test meal of 200 mL within 10 min. Furthermore patients were excluded for CSH 
testing in case of a recent (less than 3 months) myocardial infarction, transient 
ischemic attack or stroke respectively, a medical history of ventricular tachyar-
rhythmias or the presence of a carotid bruit.(18)
 The protocol conformed to the Declaration of Helsinki and informed consent 
was asked verbally prior to the tests.
Baseline Assessment
Preceding OH, PPH and CSH testing, patients underwent a complete medical 
history and physical examination. Baseline characteristics (age, gender, body 
mass index (BMI), systolic BP (SBP), diastolic BP (DBP) and heart rate (HR)) were 
measured. The presence and severity of comorbidity was recorded using the 
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Cumulative Illness Rating Scale for Geriatrics (CIRS-G), ranging from 0 to 56.(19) 
For medical history we used the following disease groups: dementia; depression 
or anxiety disorder; chronic obstructive pulmonary disease; diabetes mellitus; 
Parkinson’s disease or disorders with parkinsonism; cardiovascular disease 
(CVD) including myocardial infarction, angina pectoris, heart failure, peripheral 
vascular disease, aneurysm of the aorta, stroke, and transient ischemic attack; 
hypertension; and malignancy.
Test Protocol
Patients fasted overnight and medication was withheld from midnight the night 
before. All tests were performed in the morning or afternoon. During the tests 
BP and HR were constantly measured using a beat-to-beat finometer (FinapresTM)
(20) and a three-lead electrocardiogram (ECG). BP was measured at the 
non-dominant arm, which was held at heart level with a sling. 
 The test protocol started with the OH test, followed by the PPH test and 
finished with the carotid sinus massage (CSM). Before testing and at each 
time-point during tests (OH test every minute, PPH test every 5 min), BP and HR 
were determined. The reported BP values are averages of 20 heartbeats (10 before 
and 10 after each time-point). For CSH testing, BP values were determined by 
taking the average of 3 heartbeats around the lowest BP value during or in a 30-s 
period after CSM. From the ECG registration, the R-R interval before and the 
longest interval during or in a 30-s period after CSM were documented. At each 
time-point symptoms of possible cerebral hypoperfusion, like dizziness, light-
headedness, fatigue or loss of consciousness were noted. 
Orthostatic hypotension test
After a 10 min resting period in the supine position, patients were asked to stand 
up and remain standing for 10 min. Baseline values of BP and HR were defined 
as the average during the 60 s before rising. OH was defined as a SBP decline of 
20 mmHg or more or a DBP decline of 10 mmHg or more within 3 min of 
standing from supine.(13) 
Postprandial hypotension test 
The patient was asked to drink a test meal within 10 minutes in sitting position. 
The test meal is a solution of 100 mL glucose syrup and 100 mL lactose free milk, 
containing 292 kcal, 65 g carbohydrates, 2 g fat and 4 g protein. The meal 
temperature was 20-25 ºC.(21) After drinking the meal, BP and HR were 
monitored during 75 min. PPH  was defined as a SBP decline of 20 mmHg or 
more within 75 min after a meal.(7;9) 
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Carotid sinus massage
CSM was performed in supine position after 5 min rest. Firm, longitudinal 
massage was performed for 5 s over the site of maximal pulsation of the right 
carotid artery and repeated on the left side when SBP and HR were normalized. 
If no significant response in SBP or HR was obtained with supine CSM, the 
procedure was repeated with the patient tilted at 70º on a tilt-table with footplate. 
CSH is defined as an interruption of heart beat more than at least 3 s or as a 
decrease of SBP of 50 mmHg or more. 
Assessment of HRV, BPV, and BRS
Data were analyzed with custom-written software in Matlab (version R2010b, the 
MathWorks Inc., Natick, Massachusetts). The 10 min resting period in supine position 
was used to select an appropriate period to determine the measures of HRV, BPV, 
and BRS. Not necessarily the same periods were used to calculate HRV, BPV, or BRS. 
Heart rate variability
The standard deviation of all normal beat intervals (SDNN-HRV) and the square 
root of the mean squared difference of successive beat intervals (RMSSD-HRV) 
were used for conventional time domain measurements.(1) The data were 
linearly detrended and filtered with a third-order Butterworth filter with a 
cut-off frequency of 0.03 Hz and resampled to 4 Hz using linear interpolation. 
Artifact-free data series of 100 s were used. With spectral analysis the power of 
HRV was calculated in the low (LF-HRV; 0.04-0.15Hz) and high (HF-HRV; 
0.15-0.4Hz) frequency band as conventional frequency domain measurements.
(1) Also the ratio of LF-HRV and HF-HRV was determined (LF/HF-HRV). 
Blood pressure variability
The BPV was also analyzed in the time and frequency domain. Only the systolic 
BP was used. The standard deviation of BP (SD-SBP) and the square root of the 
mean squared difference of successive BP beats (RMSSD-SBP) were used for 
conventional time domain measurements. The data were linearly detrended and 
filtered with a third-order Butterworth filter with a cut-off frequency of 0.05 Hz 
and resampled to 1 Hz using linear interpolation. Only uninterrupted data 
series of at least 50 s were used for the spectral analysis. With spectral analysis 
the power of BPV was calculated in the low (LF-SBP;0.05-0.15Hz) and high (HF-
SBP;0.15-0.4Hz) frequency band. These frequency bands were defined largely in 
line with the standards of the European Society of Cardiology for HRV, meaning 
LF=0.04-0.15 Hz and HF=0.15-0.4 Hz.(1) However, because a filter with cut-off 
frequency 0.05 Hz was used as recommended by Bernardi et al.(22), LF for BPV 




BRS was quantified in the time domain with the sequence and the standard 
deviation method (SD-BRS) and in the frequency domain with spectral analysis. 
The sequence method was applied for positive (SQ-BRS+) and negative (SQ-BRS-) 
sequences.(23) The SD-BRS method calculates the BRS by dividing the standard 
deviation of the heartbeat interval by the standard deviation of SBP (SD-BRS). 
The SD-BRS is an easy, robust and reliable method to calculate BRS.(22)
 The data were linearly detrended and filtered with a third-order Butterworth 
filter with a cut-off frequency of 0.05 Hz and resampled to 1 Hz using linear 
interpolation. Data series of at least 50 s were used. In the frequency domain BRS 
is calculated in the low (0.05-0.15 Hz) and high (0.15-0.4 Hz) frequency band by 
dividing the spectral power of the heartbeat interval through the spectral power 
of SBP, only if the coherence more than 0.5.(24) Heartbeat intervals were derived 
from the BP peaks to overcome artifacts in the ECG.(25)
Statistical Analysis
We compared the patients with and without OH, PPH and CSH, respectively. 
We used only those patients who completed all three tests. Because there is 
frequent co-existence of multiple hypotensive syndromes in the same patient we 
also compared  patients with no single hypotensive syndrome versus one, two, 
or three hypotensive syndromes. We also compared patients with and without 
falls, dizziness or syncope as presenting symptom. Finally, we made a comparison 
between patients who presented with falls and patients who presented with 
syncope. 
 Baseline characteristics of the patients were compared with independent 
sample Student’s t-tests or one way analysis of variance and chi-square (χ2) 
statistics. Results are presented as mean ± standard deviation (SD) or percentages.
 Normality of HRV, BPV, and BRS measures was tested with the Kolmogorov-
Smirnov test. If the data were not normal distributed they were logarithmically 
transformed and tested again for normality. None of the HRV, BPV, and BRS 
measures had a normal distribution. After logarithmic transformation all data 
were normal distributed except for the SQ-BRS+, SQ-BRS- and SD-SBP data. 
Means were compared with independent sample Student’s t-tests or one way 
analysis of variance for normal distributed data, otherwise Mann-Whitney’s U 
tests or Kruskal-Wallis tests were used. Because we compared 14 different 
measures of cardiovascular autonomic function, we choose an alpha of 0.01, 
instead of 0.05 to correct for multiple testing. Results for HRV, BPV, and BRS 
measures are presented as medians with the 25th - 75th percentile range. All 
analyses were performed using the SPSS software version 16 for windows (SPSS 
Inc., Chicago, Illinois). 
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Of the 242 patients, 203 (84%) patients completed all three tests. CSM was not 
performed in 34 patients because they met the exclusion criteria. Of five patients 
there was no value for OH and/or PPH tests due to unreliable measurements (no 
good signal). Of these 203 patients, 53%, 57%, and 50% were diagnosed with OH, 
PPH and CSH and 87% patients were diagnosed with at least one or more 
hypotensive syndromes. 
 Baseline characteristics of patients with and without different hypotensive 
syndromes were compared (Table 1). Compared with the patients without OH, 
the patients diagnosed with OH had lower BMIs and had higher mean baseline 
SBP (p<0.05). The patients with PPH were older, had higher baseline SBPs and 
had more frequently a medical history of CVD (p<0.05). The patients with CSH 
had lower BMIs, presented less often with dizziness and used less angiotensin-
converting enzyme inhibitors or angiotensin-II receptor antagonists compared 
with those without CSH (p<0.05). There were no differences in comorbidity 
(CIRS-G) nor the number of drugs used.
Table 1   Comparison of the Baseline Demographic and Clinical Characteristics 
of the Patients With and Without Orthostatic Hypotension, Postprandial 













Age 76.9±8.6 78.4±7.4 75.6±8.0 79.3±7.6† 76.7±9.0 78.7±6.7
BMI 27.3±4.9 26.0±4.2* 27.3±4.7 26.1±4.4 27.2±4.8 26.0±4.2‡
Female, n(%) 55(58%) 74(69%) 59(68%) 70(60%) 63(62%) 66(65%)
Baseline SBP 162±24 171±25* 160±22 172±26† 164±25 169±25
Baseline DBP 78±11 80±13 79±12 79±12 79±12 79±12
Baseline HR 67±11 68±12 68±12 67±11 68±12 68±11
CIRS-G total score 10.6±4.6 11.3±4.4 10.5±4.3 11.3±4.6 10.9±4.4 10.9±4.5
Presenting symptom
Falls 79(83%) 96(90%) 74(86%) 101(87%) 90(89%) 85(84%)
Dizziness 48(51%) 55(51%) 41(48%) 62(53%) 61(60%) 42(42%)‡
Syncope 29(31%) 37(35%) 28(33%) 38(33%) 36(36%) 30(30%)
Symptomatic - 67(62%) - 46(40%) - 51(51%)
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Measures of HRV, BPV, and BRS
No differences were found in the different measures of HRV, BPV, and BRS 
between patients with or without OH, PPH and CSH respectively (Table 2). 
Similar results were found when patients with no versus one, two or three 
hypotensive syndromes were compared (data not shown). Also no differences 
were found in the different measures of HRV, BPV and BRS between patients 
with or without falls, dizziness and syncope respectively (Table 3). There were 
also no differences between patients who presented with falls and patients who 
presented with syncope (data not shown). 














Dementia 6(6%) 6(6%) 4(5%) 8(7%) 4(4%) 8(8%)
Depression or anxiety 15(16%) 21(19%) 20(23%) 16(14%) 19(19%) 17(17%)
COPD 16(17%) 19(18%) 15(17%) 20(17%) 16(16%) 19(19%)
Diabetes mellitus 13(14%) 16(15%) 9(10%) 20(17%) 18(18%) 11(11%)
Parkinson(ism) 4(4%) 6(6%) 3(3%) 7(6%) 7(7%) 3(3%)
CVD 31(33%) 42(39%) 20(23%) 53(46%)† 37(36%) 36(36%)
Hypertension 42(44%) 50(46%) 37(43%) 56(48%) 53(52%) 40(40%)
Malignancy 15(16%) 25(23%) 14(16%) 26(22%) 19(19%) 21(21%)
Medication use
Polypharmacy 64(67%) 76(70%) 59(68%) 81(70%) 67(66%) 73(72%)
Beta blockers 35(37%) 44(41%) 34(39%) 45(39%) 46(45%) 33(33%)
ACE/AT2 26(27%) 43(40%) 26(30%) 43(37%) 43(42%) 26(26%)‡
CCB 11(12%) 19(18%) 13(15%) 17(15%) 16(16%) 14(14%)
Diuretics 31(33%) 39(36%) 30(35%) 40(35%) 39(38%) 31(31%)
Nitrates 10(11%) 15(14%) 8(9%) 17(15%) 15(15%) 10(10%)
The results are reported as means ± standard deviations or numbers (percentages). OH, orthostatic 
hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity; age(years); BMI, 
body mass index(kg/m2); SBP, systolic blood pressure(mmHg); DBP, diastolic blood pressure(mmHg); 
HR, heart rate(beats per minute); CIRS-G, Cumulative Illness Rating Scale for Geriatrics; COPD, 
chronic obstructive pulmonary disease; CVD, cardiovascular disease; ACE/AT2, angiotensin-con-
verting enzyme inhibitors or angiotensin-II receptor antagonists; CCB, calcium channel blockers. 
*:significant differences (p<0.05) between patients with and without OH; †:significant differences 
(p<0.05) between patients with and without PPH; ‡:significant differences (p<0.05) between patients 
with and without CSH. 
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 Finally, 20 patients had delayed OH, defined as onset of OH after the third 
minute. These patients were categorized among the “no OH” patients (n=94) in 
our study. Compared with the n=74 patients without OH and without delayed 
OH, they did not differ in HRV, BPV and BRS (data not shown).
Discussion
The main finding of this study is that there were no differences in HRV, BPV and 
BRS between geriatric patients with and without hypotensive syndromes. We 
used extensive non-invasive, easy available and state of the art  indices of HRV, 
BPV, and BRS.(1;22-24). Most of these indices reflect primarily vagal activity, but 
LF-HRV and LF/HF-HRV are also thought to reflect sympathetic activity or to 
reflect the sympathovagal balance.(1)  
 Previous studies which examined the relationship between hypotensive 
syndromes and measures of HRV, BPV and BRS have reported conflicting 
results. In older persons there was an  association between diminished BRS with 
BP fall during OH testing.(26;27) However, no difference in spectral measures of 
HRV and BPV was found between patients with normal and poor orthostatic 
tolerance.(28) During intraduodenal glucose administration for PPH testing an 
association between diminished BRS with SBP fall was found.(29) Spectral 
measures of HRV were lower(30) and systolic BPV(31) was higher in patients 
with versus without PPH, but the latter study could not replicate the differences 
in HRV measures.(31) BRS was found to be higher(8), the same(32) or lower(33) 
between patients with and without CSH. Spectral measures of HRV were higher 
in patients with CSH compared with patients without CSH.(8). In another study, 
no differences were found in systolic BPV measures between patients with and 
without CSH.(34) An explanation for these conflicting data is the difference in 
used methods and in diagnoses, severity of illnesses and functional capacity 
between study populations. Another explanation is the diversity of methods 
used to measure HRV, BPV and BRS in either the time or frequency domain.(35) 
Age-related normal values for different measures of HRV, BPV and BRS are 
lacking, which makes comparison between populations difficult.(1)
 Our data add to the literature because for the first time all three hypotensive 
syndromes are meticulously characterized together in one population of 
consecutive older patients who visited a geriatric outpatient falls and syncope 
clinic. Cardiovascular autonomic dysfunction, as measured with multiple, 
non-invasive measures of HRV, BPV and BRS, was not a sufficient cause to 
explain the occurrence of these hypotensive syndromes. An explanation for our 
findings might lie in the fact that hypotensive syndromes, especially in the 
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elderly patients, are multifactorial in genesis.(36-38) The lack of an association 
between HRV, BPV, and BRS and hypotensive syndromes does not prove that 
cardiovascular autonomic control has no role in the pathophysiology of these 
hypotensive syndromes. However, it is unlikely that cardiovascular autonomic 
dysfunction is a sufficient factor, as other redundant regulatory mechanisms are 
able to compensate for diminished cardiovascular autonomic function and thus 
determine if hypotensive syndromes occur. Cardiovascular autonomic 
dysfunction probably is just a component cause with high frequency in geriatric 
patients, and therefore there is no difference to be found between these groups. 
The conflicting data from literature can easily be explained by the geriatric 
syndrome causative model, which can be filled with different combinations of 
factors in different subgroups.(36-39) 
Strengths and Limitations
This study has some limitations. Firstly, this study was a cross-sectional analysis. 
Secondly, we have no complete assessment of all 14 different measures of 
autonomic function in all 203 patients. However, for 10 measures there is 
approximately 15% or less missing data, which is acceptable. Of four variables 
the percentage of missing data was higher because for frequency analysis 
consecutive data series of 50 to 100 s are necessary which was sometimes not 
possible because the BP measurement was interrupted by calibrations, and ECG 
signals were sometimes disturbed through artifacts. Moreover, the calculation 
of the BRS with the spectral method requires that the coherence is more than 0.5, 
which explains the high portion of missing data for BRS-LF and BRS-HF. 
Datasets of 50 to 100 s are rather short to perform frequency domain analysis in 
which it is advisable to have data set lengths of at least 128 consecutive beats.(40) 
Hereby, the estimation especially of the LF measures might be less accurate. 
However, despite these shortcomings, all the results of the frequency domain 
analysis are in line with the other determined variables of HRV, BPV, and BRS. 
 Thirdly, this study investigated a selective patient population, and did not 
have a control group. All patients were referred to an out-patient geriatric falls 
and syncope clinic, because of syncope, falls and/or dizziness. This has the 
disadvantage of a specific selection and therefore our sample is not a 
representative for the general population, but only for populations referred to 
similar outpatient clinics. On the other hand, this is the geriatric population 
with the highest relevance of hypotensive syndromes. 
Finally, there is evidence that postural and postprandial BP responses vary 
during the day and therefore should be measured more than once.(12;31;41) It 
would be possible that we falsely classified patients to be without OH, PPH or 
CSH, who might in fact have the same degree of autonomic dysfunction as those 
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patients with OH, PPH or CSH. We found a high prevalence of syndromes, 
comparable to other studies, which reduces the likelihood that we missed 
patients. Also, when comparing patients with and without syncope or falls there 
still was no difference in autonomic function. Misclassification is therefore less 
likely. 
 This study has several other strengths. Firstly, the BP measurements and 
tests in our study were performed under standardized circumstances, with a 
beat-to-beat finometer (FinapresTM), which is an accurate way to measure BP 
variability.(20) 
 Secondly, we limited as much as possible the confounding effects of medication 
on our assessment of hypotensive syndromes and on our estimates of autonomic 
function. To do this, all medication was withheld from midnight the night before 
the tests. Nonetheless, biological effects of these drugs might persist longer than 
the period of abstinence, especially for beta-blockers. However, in aging beta-
adrenoreceptor responsiveness decreases by several mechanisms and the effects 
of beta-blockers are therefore less pronounced.(42) Moreover, we found no 
differences in the use of beta-blockers or other medication between patients 
with and without hypotensive syndromes, with exception of lower use of angio-
tensin-converting enzyme inhibitors and angiotensin-II receptor antagonists in 
patients with CSH. 
 Thirdly, a strength of this study is that we investigated all three hypotensive 
syndromes in the same patients, where other studies only looked at one type of 
hypotensive syndrome.(8;26-34)
 Finally, we investigated a rather large group of 203 geriatric patients on the 
presence of three common hypotensive syndromes, and this study addresses a 
potential mechanism underlying these common hypotensive syndromes.  
Conclusions
In geriatric patients with hypotensive syndromes, cardiovascular autonomic 
function as measured by HRV, BPV, and BRS is comparable to patients without 
such syndromes. These findings may favor a multifactorial pathophysiology of 
geriatric hypotensive syndromes, and argue against a single or dominant 
etiological factor, that is, cardiac autonomic dysfunction. For clinical practice 
our data underline that in the initial diagnostic work-up of elderly patients with 
falls, dizziness and syncope should follow the structured approach as proposed 
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To the Editor: With interest we have read the article by Flammang et al.(1) In 
their well-designed, controlled trial, they show convincing evidence that cardiac 
pacing in individuals with syncope of unknown origin (SUO) and a positive 
adenosine 5’-triphosphate (ATP) test, results in fewer recurrences of syncope 
than those who do not receive pacing. The ATP test thus seems to be a promising 
additive diagnostic tool to guide the decision for pacemaker implantation. 
 Their study was based on a relatively small number of 88 patients with SUO 
who had a positive ATP test, of whom 80 patients were randomized. Patients 
were ineligible if they had an implantable pacemaker or defibrillator, a 
first-degree atrioventricular block or other sinus or atrioventricular node 
conduction disorder, carotid sinus hypersensitivity or diabetes mellitus. Patients 
with SUO with a negative ATP test were excluded. The selection process in this 
study raises questions. For example, it is not clear to us why 24% of the patients 
had diabetes mellitus, if diabetes mellitus was an exclusion criterion. In addition, 
this study had a very selected population of patients in whom syncope remained 
unexplained after the usual screening tests, including, for example, investigation 
of orthostatic hypotension.
 We are, therefore, very interested in the flow of patients before randomization. 
It would be informative to place the final 80 patients in the context of the total 
number of patients with syncope, aged > 18 years, who visited the emergency 
departments or outpatient clinics of the 10 recruiting European centers between 
January 2000 and May 2005. In how many of those patients did the cause of 
syncope remain unexplained? Of these remaining patients with SUO, what was 
the percentage of patients who were ineligible? Among the eligible patients with 
SUO, what was proportion of patients with a negative ATP test? Such information 
can be useful in guiding the selection of the appropriate patients for pacing.   
 We are interested in how these results can be extrapolated to a geriatric 
population visiting a clinic dealing with falls and syncope. Carotid sinus hyper-
sensitivity is present in 39% of asymptomatic older patients.(2) orthostatic 
hypotension and carotid sinus hypersensitivity often coexist in geriatric 
patients. In only one third of the patients visiting a geriatric clinic because of 
falls and syncope could orthostatic hypotension and carotid sinus hypersensi-
tivity be excluded.(3) Furthermore, extrapolation to geriatric patients is difficult 
because syncope in geriatric patients is often not due to a single cause but 
multiple causes.(4,5) Syncope is due to a combination of age-related physiologic 
changes and comorbidities. Factors such as multifactorial causality, the lack of 
witnesses, and the overlap between falls and concomitant cognitive impairment 
all make it difficult to attribute a single diagnosis to an episode of syncope.(4)      
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 Flammang et al.(1) provide convincing evidence for an effective diagnostic 
tool and therapy in patients with SUO. However, in our opinion, the added value 
in clinical practice for a geriatric population dealing with falls and syncope has 
to be further established. 
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Orthostatic hypotension, postprandial hypotension, and carotid sinus hyper-
sensitivity are hypotensive syndromes with high prevalence in older people. 
However, their pathophysiology and prognostic significance remain largely 
unknown. 
Methods
In a retrospective cohort study of 313 consecutive patients visiting our falls 
outpatient clinic, we examined the clustering of orthostatic hypotension, 
postprandial hypotension, and carotid sinus hypersensitivity in the same 
patients, which might reflect a shared similar pathophysiology. The value of 
hypotensive syndromes presence and the degree of blood pressure decline as 
prognostic indicators for mortality was assessed using Cox proportional hazards 
analyses. 
Results
In 313 patients (mean age 78.7±8.0 years), 168 of 309 (54%), 175 of 302 (58%), and 
143 of 272 (53%) were diagnosed with orthostatic hypotension, postprandial 
hypotension, and sinus carotid hypersensitivity, respectively. There was no 
clustering of the hypotensive syndromes. During a median follow-up of 23.0 
months, 58 (19%) patients died. Orthostatic hypotension, but not postprandial 
hypotension or carotid sinus hypersensitivity, predicted mortality (hazard ratio: 
1.97; 95% confidence interval: 1.11-3.47). After adjusting for age, co-morbidity 
and other baseline characteristics, this relationship was no longer significant. 
However, orthostatic hypotension with  severe diastolic blood pressure decline 
of  ≥20 mmHg remained a powerful independent predictor of mortality (hazard 
ratio: 2.50; 95% confidence interval: 1.20-5.22). 
Conclusions
In falls clinic patients, hypotensive syndromes did not cluster and did not 
independently predict mortality. However, orthostatic hypotension with severe 
diastolic blood pressure decline was a powerful independent predictor of 
mortality and might be used prognostically as an easily available cardiovascular 
sign of increased mortality risk. 
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Introduction 
Orthostatic hypotension (OH), postprandial hypotension (PPH), and carotid 
sinus hypersensitivity (CSH) are disorders of blood pressure (BP) regulation 
with high prevalence in the elderly.(1-15) Structural and functional changes in 
the cardiovascular system and its neurohormonal regulation are associated 
with aging, may compromise BP homeostasis (4), and give rise to each of these 
hypotensive syndromes. We therefore hypothesised that hypotensive syndromes 
share a similar pathophysiology, resulting in the clustering of these three 
syndromes in the same persons. 
 Hypotensive syndromes are of clinical importance because they can cause 
fall-related injuries, limit the quality of life, and impede relevant treatment of 
concomitant diseases, such as hypertension or heart failure.(3,16) As such these 
syndromes may be indicators for frailty in the elderly population.(17) Despite 
their importance, relatively little is known about the prognostic aspects of these 
syndromes in older patients. In middle-aged patients, OH predicts all-cause 
mortality.(2,3,8,18) In older patients, an association between OH and mortality 
has been reported (6-8,12), but the results seem inconsistent.(6,15,19-21) Similarly, 
relatively little is known about PPH and CSH as predictive indicators of 
mortality, and results from previous studies do not show consistent results.
(1,4,11,22) The observed mortality may be a consequence of aging with underlying 
cardiovascular disease, and the hypotensive syndromes may be no more than a 
reflection of this cardiovascular disease. On the other hand, mortality may also 
be caused by harmful effects of hypotensive syndromes through hypoperfusion 
of organs. Hypotensive syndromes are associated with myocardial infarction 
(23,24), stroke (25) and falls and related injuries.(15)
 Definitions of hypotensive syndromes are dichotomous in nature. In 
addition to the presence of hypotensive syndromes, the amount of BP decline in 
response to a stimulus also may play an important role in mortality. A severe 
drop in BP might reflect a more compromised cardiovascular system and higher 
risk for serious complications, such as myocardial infarction, stroke and 
fall-related injury. 
 We hypothesised that hypotensive syndromes are predictors for all-cause 
mortality in a geriatric population and that there is a dose–effect relationship 
between the amount of BP decline during testing for hypotensive syndromes 
and mortality. This might be important in the selection of older patients for 
cardiological and cardiosurgical procedures. Recently, frailty has been shown to 





This retrospective study included 313 consecutive patients who were referred to 
the geriatric outpatient falls clinic of the Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, from May 2005 to June 2010 because of a 
fall, dizziness or syncope and who were able to undergo the test protocol for 
investigation of the presence of OH, PPH and CSH. The patients were judged 
able to undergo the test protocol if they were able to follow the instructions, 
could stand for 10 minutes and could drink a test meal of 200 ml within 10 
minutes. This test protocol is part of the standard care for patients who visit the 
geriatric outpatient fall clinic and conformed to the Declaration of Helsinki. 
Patients received targeted multifactorial interventions as standard medical care, 
which among others consisted of medication review with starting and/or 
stopping of medications, prescription of walking aids, and education on lifestyle 
factors and how to influence them.  
Test protocol
Before OH, PPH and CSH testing, the patients underwent a complete physical 
examination including medical history. Baseline characteristics (age, gender, 
body mass index (BMI)), baseline systolic BP (SBP), diastolic BP (DBP), medical 
history and medication use were documented. The presence and severity of 
co-morbidity was recorded using the Cumulative Illness Rating Scale for 
Geriatrics (CIRS-G).(27) This scale estimates the illness burden and diversity 
using a five-point scale (0-4, with higher scores indicating more severe morbidity) 
reflecting the severity of pathology in each of 14 categories (maximum total 
score: 56). The CIRS-G score was used to compare the co-morbidity between 
groups. The patients fasted overnight, and medication was withheld from 
midnight the night before. All tests were performed by a physician’s assistant in 
the morning or afternoon. During the tests, BP and heart rate were constantly 
measured using a beat-to-beat Finometer (FinapresTM)(28) and a three-lead elec-
trocardiogram (ECG). BP was measured at the non-dominant arm, which was 
held at heart level with a sling. Before testing and at each time point during the 
tests (OH test every minute, PPH test every 5 minutes), BP and heart rate were 
documented. The reported BP values were averages of 20 heart beats (10 before 
and 10 after each time point). For OH and PPH testing, SBP and DBP values were 
determined. For CSH, BP values were determined by averaging the values of 
three heart beats around the lowest BP value during carotid sinus massage 
(CSM) or in a 30-second period after CSM. From the ECG registration, the R-R 
interval before and the longest interval during or in a 30-second period after 
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CSM were documented. All test results were electronically recorded in a 
database after approval of the test performance.
Orthostatic hypotension test
After a 10-minute resting period in the supine position, the patients were asked 
to stand up and remain standing for ten minutes. Baseline values of BP and 
heart rate were defined as the average during the 60 seconds before rising. OH 
was defined as a SBP decline of 20 mmHg or more or a DBP decline of 10 mmHg 
or more within 3 minutes of standing from supine.(29) 
Postprandial hypotension test 
The patients were asked to drink a test meal within 10 minutes in the sitting 
position. The test meal was a solution of 100 ml glucose syrup and 100 ml 
lactose-free milk containing 292 kcal, 65 g carbohydrates, 2 g fat and 4 g protein. 
The meal temperature was 20-25ºC.(30) After drinking the meal, BP and heart 
rate were monitored over 75 minutes. PPH was defined as a SBP decline of 20 
mmHg or more within 75 minutes after a meal.(1,11) 
Carotid sinus massage
CSM was performed in the supine position after 5 minutes of rest. Firm, 
longitudinal massage was performed for 5 seconds over the site of maximal 
pulsation of the right carotid artery and repeated on the left side when the SBP 
and heart rate were normalised. If no significant response in heart rate or SBP 
was obtained with supine CSM, the procedure was repeated with the patient 
tilted at 70º on a tilt table with footplate.(31) Accepted contraindications were 
taken as exclusion criteria for CSM: a murmur over the carotid artery, myocardial 
infarction, cerebral ischemia in the past 3 months, or a history of ventricular 
tachyarrhythmia’s.(31) CSH was defined as an interruption of heart rate over at 
least three seconds (cardio-inhibitory type), as a decrease of SBP of 50 mmHg or 
more (vasodepressor type) or as a combination of both (mixed type).(29,32) 
All-cause mortality
The follow-up period ended on August 2010. Data on vital status were ascertained 
through linkages with the Dutch municipal administration. When the municipal 
administration could not provide this information, the general practitioner or the 
patient’s family was contacted. For one patient, the exact date of death was not 
discovered, and another patient was lost to follow-up because of emigration. From 
these two patients, the year and month of death and emigration were known. For 
survival analysis, we used the month as the unit of time; therefore, follow-up was 




Characteristics of the patients according to presence of BP syndromes (yes or no) 
were compared using an unpaired t-test and chi-squared (χ2) statistics. The 
results are presented as the means ± standard deviations (SD) or percentages 
unless otherwise stated. Clustering of BP syndromes was tested with chi-squared 
(χ2) statistics. 
 Cox proportional hazards models were used to identify whether OH, PPH 
and CSH status predicted mortality. The first model was unadjusted, and the 
second model was adjusted for age, gender, BMI, co-morbidity (CIRS-G score), 
medication use and baseline SBP and DBP. For medication use, we used the 
following medication groups: 1) beta blockers; 2) calcium channel blockers; 3) 
diuretics; 4) angiotensin-converting enzyme inhibitors or angiotensin II receptor 
antagonists; 5) nitrates; 6) platelet aggregation inhibitors; 7) cholesterol-lowering 
drugs, i.e., 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(statins) or fibrates; 8) psychiatric medication, i.e., antidepressants, antipsychotics 
and anxiolytics; and 9) medication for Parkinson’s disease or parkinsonism.
To examine the influence of specific disease profiling in comparison with the 
CIRS-G score, we repeated the adjusted second model with specific disease 
information from the medical histories instead of the CIRS-G scores. We used 
the following disease groups: 1) dementia; 2) depression or anxiety disorder; 3) 
chronic obstructive pulmonary disease; 4) diabetes mellitus; 5) Parkinson’s 
disease or disorders with parkinsonism; 6) the cardiovascular disease group, 
including myocardial infarction, angina pectoris, heart failure, peripheral 
vascular disease, aneurysm of the aorta, stroke, and transient ischemic attack; 7) 
hypertension; and 8) malignancy.
 The results were expressed as hazard ratios (HRs) with 95% confidence 
intervals (CIs). Because of the frequent co-existence of multiple hypotensive 
syndromes in the same patient, we also performed unadjusted and adjusted Cox 
proportional hazards analyses of patients with no versus one, two or three 
hypotensive syndromes and patients with no versus at least one hypotensive 
syndrome.
  To investigate the dose–effect relationship between mortality and the 
amount of BP decline during testing for hypotensive syndromes, SBP and DBP 
decline were divided into three subgroups (mild, moderate and severe) for each 
hypotensive syndrome. The patients were classified into the mild subgroup if 
they did not meet the BP criteria for the different hypotensive syndromes. For 
OH and PPH, the mild, moderate and severe SBP decline subgroups were 
defined as a decline of < 20 (no OH or PPH), 20 to 35, and ≥ 35 mmHg. The mild, 
moderate and severe DBP decline subgroups for OH were defined, respectively, 
as a decline of < 10 (no OH), 10 to 20, and ≥ 20 mmHg. The same subgroup 
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classification as OH was used for DBP decline in PPH. DBP decline is not a 
criterion for PPH, but a DBP decline subgroup classification was used analogous 
to the same SBP decline criterion in both OH and PPH. For CSH, the mild, 
moderate and severe SBP decline subgroups were defined, respectively, as a 
decline of < 50 (no CSH), 50 to 65 and ≥ 65 mmHg. Because DBP decline also is 
not a criterion for CSH and the DBP decline was expected to be larger than that 
in OH or PPH, the following DBP decline subgroup classification was used in 
CSH: < 15, 15 to 25 and ≥ 25 mmHg. To investigate the relationship between 
mortality and mild, moderate and severe decline of SBP and DBP during BP 
tests, Cox proportional hazards models were repeated with and without 
adjustment for age, gender, BMI, co-morbidity (CIRS-G score), medication use 
and baseline SBP and DBP. In the adjusted analysis, we also studied the influence 
of specific disease profiling in comparison with the CIRS-G score by repeating 
the adjusted second model with specific disease information from the medical 
histories instead of the CIRS-G scores. The results were considered to be 
significant for p-values < 0.05. The results were expressed as HRs with 95% CIs. 
All analyses were performed using SPSS software version 16 for windows (SPSS 
Inc., Chicago, Illinois, USA). 
Results
Baseline characteristics
Figure 1 shows the flow chart of the tested patients. Of the 313 patients, 309, 302 
and 272 completed the tests for OH, PPH and CSH, respectively. Of these 
patients, 54%, 58% and 53% were diagnosed with OH, PPH and CSH, respectively. 
Of the 143 patients with CSH, 53% had the CSH vasodepressor subtype, 11% had 
the cardio-inhibitory subtype and 36% had both subtypes. Missing values for 
OH (n = 4) and PPH (n = 11) tests were due to unreliable measurements. CSM 
was not performed in 41 (13%) patients because they met the exclusion criteria. 
In total, 261 (83%) patients completed all three tests. Of these patients, 33 (13%) 
had no hypotensive syndrome, and thus, 228 (87%) patients had at least one or 
more hypotensive syndromes. The distribution of the patients diagnosed with 
one or more hypotensive syndromes is shown in Figure 2. 
 Table 1 compares the demographic and clinical characteristics of the patients 
with and without OH, PPH and CSH. Compared with the patients without OH, 
the patients diagnosed with OH were older, had lower BMIs, were more 
frequently female, had higher mean baseline SBPs and DBPs, and used more 
angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. 
The patients with PPH were also older, had higher baseline SBPs and had more 
50
CHAPTER 3A
Figure 1   Flow chart of the tested patients 
OH, orthostatic hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity; 
VD, vasodepressor; CI, cardio-inhibitory.
Figure 2   Venn diagram of the number of patients (n = 230) with one or more 
hypotensive syndromes 
OH, orthostatic hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity. 
The patients (n = 33) with no hypotensive syndrome and those (n = 50) who did not receive all tests 
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Table 1   Comparison of the baseline demographic and clinical characteristics of 













Age 77.3 ± 8.7 79.7 ± 7.2* 76.7 ± 8.3 79.8 ± 7.6† 77.1 ± 9.1 78.9 ± 6.9
BMI 27.1 ± 4.5 25.9 ± 4.3* 26.9 ± 4.5 26.2 ± 4.4 27.2 ± 4.7 25.8 ± 4.0‡
Female, n (%) 79 (56%) 117 (70%)* 83 (65%) 108 (62%) 77 (61%) 88 (62%)
Baseline SBP 163 ± 26 174 ± 27* 159 ± 21 175 ± 28† 164 ± 25 171 ± 26‡
Baseline DBP 77 ± 12 80 ± 12* 78 ± 12 79 ± 12 78 ± 12 80 ± 12
CIRS-G total score 10.9 ± 4.7 11.8 ± 4.5 10.9 ± 4.6 11.7 ± 4.5 11.1 ± 4.7 11.3 ± 4.6
Medical history
Dementia 10 (7%) 13 (8%) 7 (6%) 14 (8%) 8 (6%) 12 (8%)
Depression or anxiety 23 (16%) 33 (20%) 28 (22%) 28 (16%) 24 (19%) 26 (18%)
COPD 26 (18%) 30 (18%) 20 (16%) 33 (19%) 21 (17%) 24 (17%)
Diabetes mellitus 30 (21%) 28 (17%) 18 (14%) 40 (23%) 25 (20%) 22 (16%)
Parkinson(ism) 6 (4%) 10 (6%) 4 (3%) 10 (6%) 8 (6%) 7 (5%)
CVD 50 (36%) 76 (45%) 42 (33%) 80 (46%)† 48 (38%) 53 (37%)
Hypertension 68 (48%) 77 (46%) 51 (40%) 91 (52%)† 68 (54%) 56 (39%)‡
Malignancy 21 (15%) 39 (23%) 23 (18%) 38 (22%) 23 (18%) 29 (20%)
Medication use
Beta blockers 55 (39%) 64 (38%) 47 (37%) 67 (38%) 55 (43%) 46 (32%)
CCB 16 (11%) 31 (19%) 21 (17%) 25 (14%) 21 (17%) 18 (13%)
Diuretics 50 (36%) 65 (39%) 47 (37%) 67 (38%) 49 (39%) 46 (32%)
ACE/AT2 38 (27%) 71 (42%)* 38 (30%) 67 (38%) 48 (38%) 41 (29%)
Nitrates 17 (12%) 18 (11%) 12 (9%) 21 (12%) 15 (12%) 13 (9%)
PAI 56 (40%) 68 (41%) 50 (39%) 71 (41%) 50 (39%) 56 (39%)
Statins/fibrates 46 (33%) 39 (23%) 36 (28%) 46 (26%) 26 (21%) 48 (34%)‡
Psychiatric drugs 61 (43%) 71 (42%) 51 (40%) 67 (38%) 51 (40%) 53 (37%)
Anti-Parkinson drugs 2 (1%) 8 (5%) 3 (2%) 6 (3%) 5 (4%) 4 (3%)
The results are reported as the means ± standard deviations or frequencies. OH, orthostatic 
hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity; age in years; BMI, 
body mass index in kg/m2; SBP, systolic blood pressure in mmHg; DBP, diastolic blood pressure in 
mmHg; CIRS-G, Cumulative Illness Rating Scale for Geriatrics; COPD, chronic obstructive 
pulmonary disease; CVD, cardiovascular disease; CCB, calcium channel blockers; ACE/AT2, angio-
tensin-converting enzyme inhibitors or angiotensin II receptor antagonists; PAI, platelet aggregation 
inhibitors. * Indicates significant differences (p < 0.05) between patients with and without OH; † 
indicates significant differences (p < 0.05) between patients with and without PPH; ‡ indicates 
significant differences (p < 0.05) between patients with and without CSH. 
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prior cardiovascular disease and hypertension. The patients with CSH had 
lower BMIs, higher baseline SBPs, less prior hypertension and used more choles-
terol-lowering drugs compared with those without CSH.
Clustering of hypotensive syndromes
able 2 shows the presence of other hypotensive syndromes in the patients with 
or without a certain index hypotensive syndrome. There was no clustering of 
hypotensive syndromes. Thus, PPH and CSH were not more prevalent in the 
patients with OH than in the patients without OH. Likewise, OH and CSH were 
not more prevalent in the patients with PPH than in the patients without PPH. 
The same was true for the prevalence of OH and PPH in patients with and 
without CSH. 
All-cause mortality
During the median follow-up period of 23.0 months (range 1 to 61 months), 58 
patients (19%) died. The risk of mortality was higher in the patients with OH 
than in the patients without OH (HR = 1.97; 95% CI 1.11-3.47). After adjustment 
for age, gender, BMI, co-morbidity (CIRS-G score), medication use and baseline 
SBP and DBP, the association was no longer significant (p = 0.30). Neither PPH 
nor CSH was significantly associated with mortality in the unadjusted or 
adjusted model (Table 3). The unadjusted and adjusted analysis of the patients 
with no versus one, two or three hypotensive syndromes and the patients with 
no versus at least one hypotensive syndrome did not reveal a significant 
difference in mortality. Adjustment for specific diseases instead of the CIRS-G 
scores did not alter the adjusted analysis.
BP decline and mortality
Table 4 shows the adjusted HRs for the different SBP and DBP decline subgroups 
during testing for the different hypotensive syndromes (there was no essential 













Diagnosis of  OH,  n (%) --- --- 63 (50%) 99 (57%) 65 (51%) 77 (54%)
Diagnosis of  PPH,  n (%) 74 (52%) 99 (59%) --- --- 65 (51%) 85 (59%)
Diagnosis of  CSH,  n (%) 65 (46%) 77 (46%) 55 (43%) 85 (49%) --- ---
OH, orthostatic hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity.
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difference compared with the unadjusted HRs). The survivals of the moderate 
and severe SBP decline subgroups during OH, PPH and CSH testing were not 
significantly different from the mild SBP decline subgroup. The same was true 
for the survival of the moderate and severe DBP decline subgroups during PPH 
and CSH testing. However, survival was significantly lower in the patients with 
a severe DBP decline (≥ 20 mmHg) during the OH test than in the other two 
subgroups after adjustment for age, gender, BMI, co-morbidity (CIRS-G score), 
medication use and baseline SBP and DBP (Figure 3; HR: 2.50; 95% CI: 1.20-5.22). 
Adjustment for specific diseases instead of the CIRS-G score did not alter the 
adjusted analysis. 
Discussion
The main finding of this study was that hypotensive syndromes did not cluster 
and did not independently predict mortality. OH was a predictor of mortality; 
however, after adjustment for covariates, OH did not remain an independent 
predictor of mortality. Nevertheless, in these geriatric patients, OH with a severe 
decline in DBP was a powerful independent predictor of mortality. 
 In our study, the hypotensive syndromes often occurred together. Fifty-seven 
per cent of the patients had at least two syndromes or more. This was in 
accordance with other studies that also have shown that OH and PPH or OH 
and CSH frequently occurred together in the same geriatric patient.(13,33-37) In 
the patients with OH, the other hypotensive syndromes were not more prevalent 
than in the patients without OH. The same was true for the patients with PPH or 
CSH. This absence of clustering of hypotensive syndromes in the same patients 
Table 3   Cox proportional hazards analysis for all-cause mortality related to 
blood pressure syndromes
Parameter Hazard ratio 95% Confidence 
interval
P-value
OH, unadjusted 1.97 1.11-3.47 0.02
OH, adjusted* 1.39 0.75-2.58 0.30
PPH, unadjusted 1.40 0.79-2.50 0.24
PPH, adjusted* 1.04 0.57-1.90 0.91
CSH, unadjusted 0.85 0.45-1.60 0.62
CSH, adjusted* 0.93 0.47-1.83 0.83
OH, orthostatic hypotension; PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity. 
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suggested different underlying pathophysiological mechanisms for the different 
hypotensive syndromes. These results corresponded with those of other studies 
that have shown no basis for a common mechanism between OH and CSH (37) 
and that patients with PPH were not necessarily also at risk for development of 
OH.(13,36) 
 Previous studies that have examined the relationship between OH, PPH or 
CSH and mortality have reported conflicting results. An explanation for this is 
the difference in populations that were studied. In middle-aged community-
dwelling individuals, OH has been shown to predict mortality.(3,8) It is difficult 
to compare studies that have investigated mortality in older people because they 
had a high diversity in diagnoses, severity of illnesses and functional capacity.
(38) OH was found to predict mortality in older people from Finland (6) and 
older Japanese men.(7) However, other studies have found no impact of OH on 
mortality in older people (4,20,21) and patients discharged from acute geriatric 
wards.(15) 
Figure 3   Cox proportional hazards cumulative survival curves with respect to 
DBP decline during OH test adjusted for age, gender, BMI, co-morbidity, 
medication use and baseline SBP and DBP 




 In the present study, there was no dose–response relationship between 
change in SBP and mortality in the different BP syndromes. Fisher et al.(4) found 
a dose–response relationship between a drop in SBP during PPH and mortality 
in low-level care residents, but this relationship was not adjusted for possible 
confounders. Aronow et al. (1) found that the mean maximal decrease in SBP 
during PPH was an independent predictor for mortality in older nursing home 
residents. These different results might be explained by the different populations 
studied, residents versus outpatient clinic visitors and possibly by the higher 
number of frail individuals in institutionalised populations compared with the 
general population. The only study on mortality and CSH did not investigate a 
dose response.(22) Several studies have found a dose–response relationship 
between decline in SBP and DBP during OH and vascular-related or all-cause 
mortality.(3,6,7) In our study during OH testing, a severe decline in DBP, but not 
SBP, increased all-cause mortality. A possible explanation might be that the 
excess mortality was caused by myocardial ischemia. DBP reductions, but not 
SBP reductions, have been associated with an increased risk of myocardial 
infarction.(23) In another study, only diastolic OH predicted coronary events.(3) 
The link between DBP drop and myocardial infarction may be related to the 
crucial role of diastolic blood flow on myocardial perfusion.(23) 
Strengths and limitations
The present study has several strengths. First, the follow-up in our study was 
complete. Second, the BP measurements and tests in our study were performed 
under standardised circumstances with a beat-to-beat Finometer (FinapressTM), 
which is an accurate way to measure BP variability.(28) Additionally, the 
exclusion of tests because of unreliable measurements was rarely required.  
 Third, co-morbidity was documented very thoroughly. The patients 
underwent full geriatric assessments with thorough anamnesis, hetero-anam-
nesis, physical examination, medical history and medication use. Co-morbidity 
was documented with the CIRS-G. The CIRS-G is frequently used in other 
studies, and good reliability and validity have been proven.(27,39) The advantage 
of using this method is that it registers not only the number of illnesses but also 
the severity of illnesses. Adjustment for specific diseases instead of the CIRS-G 
scores did not alter the results. Fourth, we included medication groups in our 
analysis, which could have influenced either mortality or the occurrence of 
hypotensive syndromes or both. Medication was withheld from midnight the 
night before the test, so only long-acting drugs possibly influenced our 
measurements. Finally, a strength of this study was that all three hypotensive 
syndromes in the same patients were investigated to determine their impact on 
mortality. Most studies have investigated only the relationship between one 
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hypotensive syndrome and mortality.(1,3,6-8,12,15,22) In one study, the influence 
of PPH and OH on all-cause mortality in older low-level care residents and PPH, 
but not OH, was found to be an independent predictor of all-cause mortality.(4) 
 The present study has some limitations. First, this study was a retrospective 
analysis, and its accuracy depended on the availability of information within 
the medical records. The patients received a multifactorial intervention, which 
could have influenced mortality. However, a systematic review and meta-analysis 
showed no influence of multifactorial intervention on mortality among older 
people in community and emergency care settings.(40) Thus, although unlikely, 
we cannot completely rule out that our results may have been confounded by 
these multifactorial interventions. Second, we analysed all-cause mortality but 
not cause-specific mortality, such as cardiovascular mortality, because it was 
impossible to reliably determine the cause of death for many patients. In older 
people, the cause of death is often unclear or related to multiple problems and 
thus, it is hard to assess validly without post-mortem data. It would be interesting 
to determine if the presence of hypotensive syndromes influenced the risk of 
hospitalisation or falls. However, it was impossible to reliably determine falls or 
hospitalisation for many patients in this retrospective analysis. Third, our 
results apply to a selection of patients who were referred to our falls clinic. 
Because of potential referral bias, our results may not be externally valid to the 
general population of elderly patients who have fallen. Fourth, the BP 
measurements were performed once, in the morning or afternoon. There is 
evidence that postural and postprandial BP responses vary during the day and 
therefore should be measured more than once.(14,41) However, there is also 
evidence that OH is more prevalent in the morning and afternoon than in the 
evening.(14,41) PPH is also more prevalent, more severe and more frequently 
symptomatic after breakfast and lunch than after diner.(36,42) The prevalences 
of the hypotensive syndromes found in our study were therefore not 
underestimated and probably accurate. Finally, it is difficult to control for all 
confounding factors in a single study. Some residual confounding may have 
persisted. 
Conclusions
In falls clinic outpatients, hypotensive syndromes did not cluster and did not 
independently predict mortality. However, OH with severe DBP decline may be 
a powerful independent predictor of mortality and may be used prognostically 
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PROGNOSTIC SIGNIFICANCE OF BLOOD-PRESSURE VARIABILITY
3
To the Editor: Peter Rothwell and colleagues(1) provide convincing evidence 
that visit-to-visit blood-pressure variability is a strong predictor of stroke, 
independent of mean systolic blood pressure. Although they do not point at a 
pathophysiological explanation, we would like to add that cerebrovascular 
reactivity is the complementary part of blood-pressure variability with regard 
to incident cerebral ischaemia,(2) and that these entities together require further 
investigation. Unfortunately, visit-to-visit heart rate variability contained no 
prognostic information about stroke occurrence. However, non-linear heart rate 
variability, rather than the traditional variability, is able to capture the long-range 
correlation that may still have prognostic value.(3) A drawback of use of 
blood-pressure variability in routine clinical management of hyper tension is 
that obtaining it requires several visits. One option to solve this is to observe 
variability in both blood pressure and heart rate continuously and non-invasively 
over some time (eg, 5–10 min) before the visit to allow direct incorporation of 
blood-pressure variability in hypertension management.(4) As mentioned by 
Rothwell and colleagues, the postural change in blood pressure, but also the less 
well studied postprandial change in blood pressure, may contain additional 
prognostic information about blood pressure regulation.(5) This study justifies a 
plea for clinicians and researchers to put more focus on the dynamics of cardio 
vascular and cerebrovascular regulation, especially in older people because of 
the high prevalence of vascular events, the lack of predictive value of the classic 
risk factors (eg, cholesterol, hypertension) in old age, and because the predictive 
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To the Editor: With interest we have read the article by Fedorowski et al.(1), 
which provides valuable information about cause-specific mortality in 
middle-aged subjects with orthostatic hypotension. In their study orthostatic 
hypotension (defined as a decrease in systolic blood pressure ≥20 mmHg and/or 
decrease in diastolic blood pressure ≥10 mmHg within three minutes of 
standing) was associated with mortality through injuries and neurologic 
diseases. Our major comment is that the article lacks data on the postural 
diastolic pressure response, both in describing the whole group with orthostatic 
hypotension, and the analyses of all cause and cause-specific mortality.
 Surprisingly, orthostatic hypotension and postural systolic blood pressure 
decline was not associated with cardiovascular mortality, although there was 
such an association in a smaller rescreened subsample. In other studies orthostatic 
hypotension was associated with myocardial infarction in middle-aged adults(2) 
and home dwelling elderly(3). Unfortunately Fedorowski et al.(1) did not study 
the influence of postural diastolic blood pressure decline on cause-specific 
mortality. There might be a crucial role of diastolic blood flow on myocardial 
perfusion and subsequently myocardial infarction and cardiovascular mortality.
(3) Postural diastolic, but not systolic blood pressure decline, seems to be 
associated with an increased risk of myocardial infarction.(3) Moreover, in the 
same study population of the Malmö Preventive Project already the association 
was found that postural diastolic, but not systolic blood pressure decline predicts 
coronary events.(4) 
 In conclusion, Fedorowski et al.(1) added very valuable information to the 
current knowledge of orthostatic hypotension through information on 
cause-specific mortality.  However, we miss in their study specific data on 
cause-specific mortality in relation to postural diastolic blood pressure decline 
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Normally, standing up causes a blood pressure drop within 15 seconds, followed 
by recovery to baseline driven by blood pressure control mechanisms. The 
prognostic value of this initial blood pressure drop, but also of the recovery 
hereafter, is unknown. The aim of this study was to examine the prognostic 
value of these blood pressure characteristics in response to standing.  
Methods
In a retrospective cohort study of 238 consecutive patients visiting our falls 
outpatient clinic, we examined the relation between all-cause mortality and 
blood pressure decline and recovery directly after active standing up with Cox 
proportional hazards analyses.   
Results
Of 238 patients (mean age 78.4±7.8 years), during a median follow-up of 21.0 
months, 36(15%) patients died. Neither absolute nor relative (%) initial blood 
pressure drop after standing predicted mortality. In contrast, the magnitude 
of blood pressure recovery 40 to 60 seconds after standing was associated 
with mortality, even after adjustment for age, co-morbidity and other baseline 
characteristics. When systolic blood pressure had recovered to less than 80% 
of pre-standing baseline after 60 seconds of standing, this was a powerful 
independent predictor of mortality (hazard ratio:3.00;95% confidence interval: 
1.17-7.68). 
Conclusions
Failure to recover from blood pressure decline in the first minute after active 
standing up is associated with excess mortality in falls clinic patients. A recovery 
of systolic blood pressure to less than 80% of baseline after 60 seconds may be 
used as an easy available cardiovascular marker for increased mortality risk in 
older falls clinic patients.
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Introduction 
The blood pressure (BP) response after standing up has two main components. 
The first component is a BP decline (often preceded by a small transient initial 
increase in BP, possibly due to leg and abdominal muscle tensing) within the 
first 15 seconds due to a mismatch in blood volume entering and leaving the 
arterial vasculature. Upon standing, cardiac output increases due to the shift of 
blood to the thorax as a consequence of compression of leg and splanchnic 
venous vessels(1-3). However, despite this increase in cardiac output, BP 
decreases -after the transient small rise- because total peripheral resistance is 
reduced to a further degree than cardiac output is increased, due to instantaneous 
vasodilatation in the active leg muscles.(1,4-8) After about 15 seconds the second 
component follows, and this is the recovery of BP by counteracting regulatory 
mechanisms of the arterial baroreflex.(3) 
 Regarding the first component, when the initial drop in BP is severe, this 
may pose a risk of serious complications, such as falls, fall-related injury, 
syncope and directly or indirectly myocardial infarction, stroke and even 
mortality.(9-11) Pathophysiologically, these negative outcomes can be related to 
insufficient perfusion of the brain and the myocardium. 
 For the second component, an impaired recovery of BP after standing 
prolongs this state of insufficient perfusion of vital organs. In addition, impaired 
recovery of BP after standing may reflect compromised cardiovascular control, 
and may be an indication of underlying disease. The prognostic meaning of 
these two components of the BP response after standing (i.e drop and recovery) 
are unknown. Recovery patterns of systolic BP (SBP) after standing have been 
studied but did not show an association with falls and frailty(12), however the 
relation of these patterns with mortality has not been studied. We hypothesized 
that both the severity of BP decline after standing and the level of impairment of 




This retrospective study included 313 consecutive patients who were referred to 
the geriatric outpatient falls clinic of the Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, from May 2005 to June 2010. Patients were 
referred because of a fall, dizziness or syncope. All patients were tested with a 
standing up test. This was part of a standardized diagnostic test protocol which 
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has been described in detail elsewhere.(13) According to the Declaration of 
Helsinki informed consent was asked verbally prior to the tests.
Baseline assessment
Patients underwent a complete medical history and physical examination before 
testing. Baseline characteristics (age, gender, body mass index (BMI), SBP, 
diastolic BP (DBP), heart rate, medical history and medication use) were 
documented. The presence and severity of co-morbidity was recorded using the 
Cumulative Illness Rating Scale for Geriatrics (CIRS-G, ranging 0-56).(14) 
 We categorized medical history in the following disease groups: 1) dementia; 
2) depression or anxiety disorder; 3) chronic obstructive pulmonary disease; 4) 
diabetes mellitus; 5) Parkinson’s disease or disorders with parkinsonism; 6) the 
cardiovascular disease group, including myocardial infarction, angina pectoris, 
heart failure, peripheral vascular disease, aortic aneurysm, stroke, and transient 
ischemic attack; 7) hypertension; and 8) malignancy.
 For medication use the following medication groups were used: 1) beta- 
blockers; 2) calcium-channel-blockers; 3) diuretics; 4) angiotensin-converting enzyme 
inhibitors or angiotensin II receptor antagonists; 5) nitrates; 6) platelet aggregation 
inhibitors; 7) cholesterol-lowering drugs, i.e., 3-hydroxy-3-methylglutaryl coenzyme-
A-reductase inhibitors (statins) or fibrates; 8) psychiatric medication, i.e., anti-
depressants, antipsychotics and anxiolytics; 9) medication for Parkinson’s 
disease or parkinsonism and 10) alpha-blockers.
Testing and data acquisition
The patients fasted overnight, and medication was withheld from midnight the 
night before. During testing, BP and heart rate were constantly measured using 
a Finometer (FinapresTM)(15) and a three-lead electrocardiogram. BP was 
measured at the non-dominant arm, which was held at heart level with a sling. 
The hydrostatic height correction system was used throughout the study to 
compensate for changing of the hand positions relative to heart level. The BP 
measurements were calibrated against brachial artery BP at baseline using the 
return to flow calibration system.(16,17) The raw data of BP and heart rate were 
stored in a data file. Unfortunately from 71 patients these raw data files could 
not be retrieved. This was a random selection, due to theft of the test laptop 
before back-up. Four patients were excluded because the BP measurements were 
not adequately determined, leaving 238 patients for analysis in the final sample. 
Data were exported using BeatscopeTM 1.1a software and  analyzed with 
custom-written software in Matlab (version R2010b, The MathWorks Inc., Natick, 
Massachusetts, USA). After a 10-minute resting period in the supine position, 
the patients were instructed to stand up as quickly as possible, sometimes with 
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a helping hand, and remain standing for 10 minutes. Baseline values of BP and 
heart rate were defined as the average during the 20 seconds before standing up. 
Hemodynamic response after active standing
For the first component of the hemodynamic response after standing we selected 
the decline of BP within the first 15 seconds. We determined the absolute 
maximum drop of SBP (∆SBP) and the lowest SBP value that was reached in 
these first 15 seconds. The lowest SBP value (SBP min) was expressed as a 
percentage of baseline (pre-standing) SBP: %SBPmin = baseline SBP−∆SBP x100%  baseline SBP 
For example if after standing up the SBP decreased from 120 mmHg to 90 mmHg 
this corresponds to a ∆SBP of 30 mmHg and a %SBPmin of 100 X (120 – 30)/120 
= 75%. We did the same for DBP (∆DBP and %DBPmin). 
 The second component of the hemodynamic response after active standing is 
the recovery of BP after the first 15 seconds. Therefore, the time between 15 to 60 
seconds after standing was divided in nine time intervals of 5 seconds.  For each time 
interval the average SBP and DBP was calculated as percentage of the baseline 
BP (%SBP15-20,%SBP20-25,....,%SBP55-60 and %DBP15-20,%DBP20-25,....,%DBP55-60). On 
the basis of the percentage SBP recovery at 55-60 seconds (%SBP55-60), we 
classified the patients into three groups with different recovery patterns in 
analogy to the earlier mentioned study of the association of SBP recovery 
patterns after standing with falls and frailty.(12) We used this time interval 
because after 60 seconds the period of interest for “classical” orthostatic 
hypotension starts. We defined patients with a full-recovery pattern to have 
recovery to >95% of their baseline SBP. The patients with a partial-recovery 
pattern had 80-95% and patients with a no-recovery pattern had <80% recovery. 
All-cause mortality
The follow-up period ended on August 2010. Data on vital status were ascertained 
through linkages with the Dutch municipal administration. When the municipal 
administration could not provide this information, the general practitioner or 
the patient’s family was contacted. For one patient, the exact date of death was 
not discovered, and another patient was lost to follow-up because of emigration. 
From these two patients, the year and month of death and emigration were 
known. For survival analysis, we used the month as the unit of time. Therefore, 
follow-up was complete for all patients. 
Statistical analysis
Characteristics of the patients were compared with one way analysis of variance, or 
Kruskal-Wallis tests according to their recovery pattern. The results are presented as 
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the means ± standard deviations or percentages unless otherwise stated. 
 Cox proportional hazards models were used to identify whether ∆SBP, 
∆DBP, %SBPmin and %DBPmin predicted mortality. The influence of the 
recovery of BP on mortality was studied with the same analyses on %SBP15-20 to 
%SBP55-60 and %DBP15-20 to %DBP55-60. Finally the same was done for the three 
recovery patterns. All above mentioned analyses were performed with two Cox 
proportional hazards models The first model was unadjusted. The second model 
was adjusted for age, gender, BMI, co-morbidity (CIRS-G score), and baseline 
SBP, DBP and heart rate. The results were expressed as hazard ratios (HRs) with 
95% confidence intervals (CIs).The results were considered to be significant for 
p-values<0.05. All analyses were performed using SPSS software version 16 for 
windows (SPSS Inc., Chicago, Illinois, USA). 
Results
Baseline characteristics
The mean age of the 238 patients was 78.4±7.8 year and 64% was female. Examples 
of the three different recovery patterns are shown in Figure 1.
 Table 1 describes the characteristics of the patients in the different recovery 
patterns. 95 patients (40%), 98 patients (41%) and 45 patients (19%) showed a full-, 
partial- or no-recovery response, respectively. Patients with no-recovery had a 
lower BMI than patients with a full- or partial-recovery (p<0.05). Patients with 
partial-recovery more often used calcium-channel-blockers than patients with 
full-recovery (p<0.05). Patients with no-recovery more often used anti-Parkinson 
medication than patients with a full-recovery (p<0.05). 
Hemodynamic response after active standing
The mean overall change in SBP and DBP were 42±25 mmHg and 23±15 mmHg, 
respectively for the whole group of 238 patients. Table 2 gives the results for 
∆SBP, %SBPmin, %SBP55-60 and ∆DBP, %DBPmin, %DBP55-60 respectively. The 
absolute initial drop of SBP and DBP did not differ between the three recovery 
groups, however as percentage of baseline %SBPmin and %DBPmin were 
slightly larger for the full-recovery response, compared to the partial- and 
no-recovery response. Figure 2 shows the mean relative SBP and DBP responses 
of the patients with the three different recovery patterns. In the initial 15 
seconds, these patterns are more or less the same, however after 15 seconds the 
patterns become substantially different from each other.  
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Figure 1   Examples of blood pressure recordings for three different blood pressure 
recovery patterns 
A: full-recovery; B: partial-recovery; C: no-recovery. At time=0 seconds patients began to stand up 




During the median follow-up period of 21.0 months (range 1-61 months), 36 
patients (15%) died. There were 8, 16, and 12 deaths in the 95, 98 and 45 patients 
with a full-, partial- or no-recovery response, respectively. There was no 
association between ∆SBP, ∆DBP, %SBPmin and %DBPmin and mortality in the 
unadjusted model (HR respectively: 1.01(95%CI 0.99-1.02); 1.00(95%CI 0.98-1.02); 
0.99(95%CI 0.97-1.01) and 1.00(95%CI 0.98-1.01)). 
 During recovery of SBP after active standing, %SBP15-20, %SBP30-35 and 
%SBP40-45-%SBP55-60 were significantly associated with mortality, even after 
adjustment for age, gender, BMI, co-morbidity (CIRS-G score), baseline SBP, 
baseline DBP and baseline heart rate. The same was true for the recovery of DBP 
at %DBP25-30 and %DBP35-40-%DBP55-60, although after adjustment this was no 
longer significant for %DBP25-30 (Figure 3).The no-recovery group had a higher 
mortality risk than the full-recovery group (HR=2.94;95%CI 1.20-7.19). The partial- 
recovery group had an intermediate risk with a HR of 1.77 but this was not 
significant. The same pattern persisted after adjustment for baseline characteristics 
with HRs of 3.00(95%CI 1.17-7.68) and 1.95(95%CI 0.49-1.87) respectively for the 
no- and partial-recovery groups (Table 2). Since calcium-channel-blocker and 
anti-Parkinson medication use differed between the different recovery patterns 
(Table 1), we additionally adjusted for these, but this did not alter the results 
(Table 3). Figure 4 shows the adjusted Cox proportional hazards cumulative 
survival curves with respect to the three different recovery patterns.
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Table 1   Comparison of the Baseline and Clinical Characteristics of the Patients 








Age 78.1±8.7 78.0±7.4 79.6±6.5
BMI 27.0±4.7 27.0±4.6 24.7±3.9†‡
Female, n(%) 55 (58%) 69 (70%) 29 (64%)
Baseline Systolic BP 167±25 167±28 170±33
Baseline Diastolic BP 78±12 83±21 79±10
Baseline heart rate 68±12 69±11 68±13
CIRS-G 11.1±4.6 11.1±4.5 10.8±4.4
Medical history
Dementia 7 (7%) 5 (5%) 4 (9%)
Depression or anxiety 17 (18%) 18 (18%) 9 (20%)
COPD 15 (16%) 24 (25%) 5 (11%)
Diabetes mellitus 14 (15%) 18 (18%) 4 (9%)
Parkinson(ism) 2 (2%) 5 (5%) 4 (9%)
CVD 35 (37%) 40 (41%) 21 (47%)
Hypertension 43 (45%) 48 (49%) 23 (51%)
Malignancy 17 (18%) 17 (17%) 14 (31%)
Medication use
Beta-blockers 32 (36%) 46 (47%) 32 (34%)
CCB 9 (10%) 22 (22%)* 7 (16%)
Diuretics 36 (38%) 36 (37%) 16 (36%)
ACE/AT2 32 (34%) 38 (39%) 17 (38%)
Nitrates 14 (15%) 13 (13%) 4 (9%)
PAI 38 (40%) 35 (36%) 19 (42%)
Statins/fibrates 31 (33%) 25 (26%) 9 (20%)
Psychiatric drugs 41 (43%) 30 (31%) 20 (44%)
Anti-Parkinson drugs 1 (1%) 2 (2%) 4 (9%)†
Alpha-blockers 4 (4%) 3 (3%) 4 (9%)
Results are reported as means ± standard deviations or numbers (percentages). Age(years); BMI, 
body mass index(kg/m2); BP, blood pressure(mmHg); heart rate(beats per minute); CIRS-G, 
Cumulative Illness Rating Scale for Geriatrics; COPD, chronic obstructive pulmonary disease; CVD, 
cardiovascular disease; CCB, calcium-channel-blockers; ACE/AT2, angiotensin-converting enzyme 
inhibitors or angiotensin-II receptor antagonists; PAI, platelet aggregation inhibitors; *:significant 
differences (p<0.05) between patients with full-recovery and partial-recovery; †:significant 
differences (p<0.05) between patients with full-recovery and no-recovery; ‡:significant differences 
(p<0.05) between patients with partial-recovery and no-recovery.
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Figure 3   Cox proportional hazards ratios of %SBP and %DBP at different time 
intervals after active standing adjusted for age, gender, body mass index, 
co-morbidity, baseline SBP, baseline DBP and baseline heart rate 
%SBP, percentage of the baseline systolic blood pressure; %DBP, percentage of the baseline diastolic 
blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Figure 2   Mean blood pressure response in percentage from baseline upon active 
standing for the different systolic blood pressure recovery patterns 
%SBP, percentage of the baseline systolic blood pressure; %DBP, percentage of the baseline diastolic 
blood pressure.
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Table 2   Comparison of the results of the Patients with different blood pressure 








∆SBP (mmHg) 36±24 44±25 50±23
%SBPmin (%) 79±13 74±16* 70±24†
%SBP55-60 (%) 104±7 88±4* 69±12†‡
Diastolic Blood Pressure
∆DBP (mmHg) 19±12 27±19 25±12
%DBPmin (%) 76±15 68±16* 68±18†
%DBP55-60 (%) 102±11 91±12* 76±14†‡
Results are reported as means ± standard deviations. *:significant differences (p<0.05) between 
patients with full-recovery and partial-recovery; †:significant differences (p<0.05) between patients 
with full-recovery and no-recovery; ‡:significant differences (p<0.05) between patients with partial-
recovery and no-recovery. 
Figure 4   Cox proportional hazards cumulative survival curves with respect to 
different systolic blood pressure recovery patterns after active standing 
adjusted for age, gender, body mass index, co-morbidity, baseline SBP, 
baseline DBP and baseline heart rate 
Full-recovery:>95% recovery of baseline SBP at 55-60 seconds; Partial-recovery:80-95% recovery of 
baseline SBP at 55-60 seconds; No-recovery:<80% recovery of baseline SBP at 55-60 seconds. SBP, 




The gravitational effects of standing up on cardiovascular hemodynamics lead 
to an initial fall in blood pressure that under normal conditions is restored to 
baseline within one minute. The main finding of this study is that impaired BP 
recovery in this first minute after standing predicts mortality, whereas the 
magnitude of BP decline within the first 15 seconds does not. The magnitude of 
the initial BP decline that follows standing up is a reflection of  hydraulic 
mechanical properties of the vasculature (leg muscle pumping, abdominal 
compression, instantaneous vasodilatation)(3), whilst the subsequent recovery 
of BP reflects active functioning of the arterial baroreflex, the major mechanism 
involved in short-term BP regulation.(3) 
 The maximum SBP (42±25 mmHg) and DBP (23±15 mmHg) decline in our 
study was higher than in a previous study with 40 healthy subjects older than 70 
years of age (26±23 mmHg and 12±18 mmHg, respectively).(18) This could be the 
result of involuntary Valsalva straining during standing up in our study, for 
which we did not explicitly control.(19,20). More likely, it is the result of studying 
different populations, i.e. very healthy and active elderly subjects versus elderly 
who visit a geriatric outpatient falls clinic. Our results were in line with a study 
in 442 community-dwelling elderly that reported a mean maximum SBP and 
DBP decline of 36 mmHg and 24 mmHg, respectively.(12) 
Table 3   Cox proportional hazards analysis for all-cause mortality related to 
recovery pattern of systolic blood pressure after active standing
Recovery Pattern Hazard ratio 95% Confidence interval P-value
Full-recovery (>95%) 1 -- --
Partial-recovery (80-95%) 1.77 0.76-4.12 0.19
No-recovery (<80%) 2.94 1.20-7.19 0.02
Full-recovery (>95%)* 1 -- --
Partial-recovery (80-95%)* 1.95 0.49-1.87 0.14
No-recovery (<80%)* 3.00 1.17-7.68 0.02
Full-recovery (>95%)† 1 -- --
Partial-recovery (80-95%)† 2.20 0.90-5.40 0.09
No-recovery (<80%)† 3.09 1.21-7.89 0.02
*:adjusted for age, gender, body mass index, co-morbidity, baseline systolic blood pressure, baseline 
diastolic blood pressure and baseline heart rate. 
†:adjusted as * and also for calcium-channel-blockers and anti-Parkinson medication use.
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 We did not measure the exact time it took to assume the upright position, 
but it is known that elderly subjects need a longer time to stand up (3–9 s) than 
younger subjects (2–3 s).(21) This likely explains why the curves in Figure 2 are 
slightly shifted rightward compared to younger subjects.(8,22) Still, the curves 
are in line with the three different BP response patterns that have been 
recognized by cluster analysis.(12)
 Our data add to the literature because for the first time to the authors’ 
knowledge the impact on mortality of the immediate response of BP in the first 
minute upon active standing has been studied. There were no differences in 
co-morbidities and cardiovascular disease prevalence or hypertension between 
the three different recovery pattern groups. The observed higher mortality in 
the no-recovery group might therefore be a consequence of dysfunctional 
regulatory autonomic function, although hypotensive syndromes in geriatric 
patients are not explained by autonomic dysfunction alone.(23) The persistent 
BP decline and resulting hypoperfusion of organs might directly result in 
syncope, falls and even mortality. However, seen as a causal risk factor, not the 
amount, but the duration of the BP decline might be of more importance for 
mortality risk. This is in line with the observation that duration of SBP decline 
following active standing or sinus carotid massage is more important as a 
determinant of symptoms than SBP nadir or delta.(24,25) 
 However, a non-causal indirect relation of an impaired BP recovery (as a 
risk marker) with mortality is more likely. Active standing is a perturbation test, 
which elicits a more or less similar response in the initial BP decline in all 
subjects. However the regulatory capacity to normalize this perturbation largely 
differs between subjects. This failure to normalize BP is associated with excess 
mortality. In this context BP recovery in the first minute after active standing 
can be seen as a physical sign that reflects a final common pathway of various 
forms of subclinically impaired physiology.(26) Therefore, this BP recovery 
pattern fits in the search for easy, simple and non-invasive indicators of mortality 
in elderly people as for example gait speed or the (modified) physiologic index.
(27-29)
 For clinical application, the results of these two components of the BP 
response after standing (i.e drop and recovery) should be related to the well 
known syndrome of orthostatic hypotension. Orthostatic hypotension is defined 
as a drop in SBP of at least 20 mmHg, (30 mmHg in case of hypertension with 
resting SBP greater than 160 mmHg) and/or 10 mmHg in DBP often measured 
between 1 and 3 minutes after standing.(30) The percentage of patients with 
orthostatic hypotension increased from 18% (17/94) in the full-recovery patients 
to 55% (53/97) and 100% (45/45) in the partial- and no-recovery patients 
respectively. In our previous study there was no relation between orthostatic 
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hypotension and mortality after adjustment for confounders.(13) Therefore the 
recovery of SBP after 1 minute should be regarded as easily obtainable, additional 
information having better predictive value for mortality than the presence or 
absence of orthostatic hypotension. 
Strengths and limitations
The present study has several strengths. Firstly, the follow-up in our study was 
complete. Secondly, the BP measurements in our study were performed under 
standardized circumstances, with a beat-to-beat finometer, which is an accurate 
way to measure BP variability.(31) Thirdly, co-morbidity was documented very 
thoroughly with the CIRS-G. The CIRS-G is frequently used in other studies, 
and good reliability and validity have been proven.(14,32) Fourthly, confounding 
effects of medication on the BP response were limited as much as possible. All 
medication was withheld from midnight the night before the test. Moreover 
there were no differences in medication use, except that patients with an 
impaired recovery (partial and no-recovery pattern) used more anti-Parkinson 
medication or calcium-channel-blockers. However, post-hoc correction for this 
medication use did not change the relation with mortality for these patients. 
Finally, we investigated a rather large group of 238 elderly patients on the 
relation of their response upon standing and mortality.  
 The present study has also some limitations. Firstly, this study was a 
retrospective analysis. The patients received a multifactorial falls intervention, 
which could have influenced mortality. However, a systematic review and 
meta-analysis showed no influence of multifactorial falls intervention on 
mortality among older people in community and emergency care settings.(33) 
Thus, although unlikely, we cannot completely rule out that our results may 
have been confounded by these multifactorial interventions. Secondly, we 
analyzed all-cause mortality but not cause-specific mortality, because it was 
impossible to reliably determine the cause of death. In older people, the cause of 
death is often unclear or related to multiple problems and thus, it is hard to 
validly assess without post-mortem data. Finally, this study investigated a 
selected patient population. All patients were referred because of syncope, falls 
and/or dizziness. This has the disadvantage of a specific selection and therefore 
our sample is not representative for the general population, but only for 
populations referred to similar outpatient clinics. On the other hand, this is the 
geriatric population with the highest relevance of BP dysregulation. 
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Conclusions
In falls clinic patients, failure to recover from BP decline in the first minute after 
active standing is associated with excess mortality. Therefore, SBP recovery to 
less than 80% from baseline after 60 seconds may be used as an easy available 




(1)  Tanaka H, Sjoberg BJ, Thulesius O. Cardiac output and blood pressure during active and passive 
standing. Clin Physiol. 1996;16(2):157-170.
(2)  ten Harkel AD, van Lieshout JJ, Karemaker JM, Wieling W. Differences in circulatory control in 
normal subjects who faint and who do not faint during orthostatic stress. Clin Auton Res. 
1993;3(2):117-124.
(3)  Wieling W, Krediet CT, van DN, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: 
review of a forgotten condition. Clin Sci (Lond). 2007;112(3):157-165.
(4)  Sprangers RL, Wesseling KH, Imholz AL, Imholz BP, Wieling W. Initial blood pressure fall on 
stand up and exercise explained by changes in total peripheral resistance. J Appl Physiol. 
1991;70(2):523-530.
(5)  Wieling W, Dambrink JH, Borst C. Cardiovascular effects of arising suddenly. N Engl J Med. 
1984;310(18):1189.
(6)  Wieling W, Harms MP, ten Harkel AD, van Lieshout JJ, Sprangers RL. Circulatory response 
evoked by a 3 s bout of dynamic leg exercise in humans. J Physiol. 1996;494 ( Pt 2):601-611.
(7)  Borst C, Wieling W, van Brederode JF, Hond A, de Rijk LG, Dunning AJ. Mechanisms of initial 
heart rate response to postural change. Am J Physiol. 1982;243(5):H676-H681.
(8)  Borst C, van Brederode JF, Wieling W, van Montfrans GA, Dunning AJ. Mechanisms of initial 
blood pressure response to postural change. Clin Sci (Lond). 1984;67(3):321-327.
(9)  Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as 
a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 
2000;31(10):2307-2313.
(10)  Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic 
hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The 
Malmo Preventive Project). Eur Heart J. 2010;31(1):85-91.
(11)  Weiss A, Beloosesky Y, Kornowski R, Yalov A, Grinblat J, Grossman E. Influence of orthostatic 
hypotension on mortality among patients discharged from an acute geriatric ward. J Gen Intern 
Med. 2006;21(6):602-606.
(12)  Romero-Ortuno R, Cogan L, Foran T, Kenny RA, Fan CW. Continuous noninvasive orthostatic 
blood pressure measurements and their relationship with orthostatic intolerance, falls, and 
frailty in older people. J Am Geriatr Soc. 2011;59(4):655-665.
(13)  Lagro J, Laurenssen NC, Schalk BW, Schoon Y, Claassen JA, Rikkert MG. Diastolic blood 
pressure drop after standing as a clinical sign for increased mortality in older falls clinic 
patients. J Hypertens. 2012;30:1195-1202.
(14)  Miller MD, Paradis CF, Houck PR et al. Rating chronic medical illness burden in geropsychiatric 
practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 
1992;41(3):237-248.
(15)  Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger 
arterial pressure monitoring: assessment of the technology. Cardiovasc Res. 1998;38(3):605-616.
(16)  Guelen I, Westerhof BE, van der Sar GL et al. Finometer, finger pressure measurements with the 
possibility to reconstruct brachial pressure. Blood Press Monit. 2003;8(1):27-30.
(17)  Guelen I, Westerhof BE, van der Sar GL et al. Validation of brachial artery pressure reconstruction 
from finger arterial pressure. J Hypertens. 2008;26(7):1321-1327.
(18)  Imholz BP, Dambrink JH, Karemaker JM, Wieling W. Orthostatic circulatory control in the 
elderly evaluated by non-invasive continuous blood pressure measurement. Clin Sci (Lond). 
1990;79(1):73-79.
(19)  Sprangers RL, Veerman DP, Karemaker JM, Wieling W. Initial circulatory responses to changes 
in posture: influence of the angle and speed of tilt. Clin Physiol. 1991;11(3):211-220.
(20)  Silber HA, Trost JC, Johnston PV et al. Finger photoplethysmography during the Valsalva 
maneuver reflects left ventricular filling pressure. Am J Physiol Heart Circ Physiol. 
2012;302(10):H2043-H2047.
91
BLOOD PRESSURE RECOVERY AND MORTALITY
4
(21)  Dambrink JH, Wieling W. Circulatory response to postural change in healthy male subjects in 
relation to age. Clin Sci (Lond). 1987;72(3):335-341.
(22)  Sprangers RL, Wesseling KH, Imholz AL, Imholz BP, Wieling W. Initial blood pressure fall on 
stand up and exercise explained by changes in total peripheral resistance. J Appl Physiol. 
1991;70(2):523-530.
(23)  Lagro J, Meel-van den Abeelen A., de Jong DL, Schalk BW, Olde Rikkert MG, Claassen JA. 
Geriatric Hypotensive Syndromes Are Not Explained by Cardiovascular Autonomic 
Dysfunction Alone. J Gerontol A Biol Sci Med Sci. 2013;68(5):581-9.
(24)  Romero-Ortuno R, Cogan L, Fan CW, Kenny RA. Intolerance to initial orthostasis relates to 
systolic BP changes in elders. Clin Auton Res. 2010;20(1):39-45.
(25)  Krediet CT, Parry SW, Jardine DL, Benditt DG, Brignole M, Wieling W. The history of diagnosing 
carotid sinus hypersensitivity: why are the current criteria too sensitive? Europace. 2011;13(1):14-
22.
(26)  Wieling W, Schatz IJ. The consensus statement on the definition of orthostatic hypotension: a 
revisit after 13 years. J Hypertens. 2009;27(5):935-938.
(27)  Newman AB, Boudreau RM, Naydeck BL, Fried LF, Harris TB. A physiologic index of 
comorbidity: relationship to mortality and disability. J Gerontol A Biol Sci Med Sci. 2008;63(6):603-
609.
(28)  Sanders JL, Boudreau RM, Penninx BW et al. Association of a Modified Physiologic Index with 
mortality and incident disability: the Health, Aging, and Body Composition study. J Gerontol A 
Biol Sci Med Sci. 2012;67(12):1439-1446.
(29)  White DK, Neogi T, Nevitt MC et al. Trajectories of Gait Speed Predict Mortality in Well-Func-
tioning Older Adults: The Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med 
Sci. 2013;68(4):456-64.
(30)  Freeman R, Wieling W, Axelrod FB et al. Consensus statement on the definition of orthostatic 
hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton 
Res. 2011;21(2):69-72.
(31)  Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger 
arterial pressure monitoring: assessment of the technology. Cardiovasc Res. 1998;38(3):605-616.
(32)  Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453-471.
(33)  Gates S, Fisher JD, Cooke MW, Carter YH, Lamb SE. Multifactorial assessment and targeted 
intervention for preventing falls and injuries among older people in community and emergency 




Baroreflex function is  
reduced in Alzheimer's disease:  
a candidate biomarker?
Joep Lagro*










The baroreflex (BR) reflects autonomic blood pressure control. Alzheimer’s 
disease (AD) affects the autonomic system. Detailed properties of BR in AD are 
unknown. We hypothesized that BR is reduced in AD, and is influenced by 
autonomic effects of cholinesterase inhibitors (ChEI).
Methods
BR was determined in 18 AD patients, 11 patients with mild cognitive impairment 
(MCI) and 19 healthy control subjects. In AD, BR was measured again after ChEI 
treatment. Receiver operating characteristic (ROC) analysis was used to define a 
BR cut-off value, which was then tested in an independent validation sample of 
16 AD, 18 MCI and 18 control subjects.
Results
BR was lower in AD compared to MCI (p<0.05) and in MCI compared to healthy 
control subjects (p<0.01). ROC analysis between AD and healthy control subjects 
yielded a sensitivity of 89% and a specificity of 94%. ChEI treatment increased 
BR with 66% (p<0.01).
Conclusions
BR was reduced in AD and increased after treatment with ChEI. BR may be a 
good biomarker to further explore the link between cardiovascular disease and 
AD. 
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the 
leading cause of dementia. Worldwide, AD is among the top 5 of most costly 
diseases and places a huge burden on individual caregivers.(1)  There is still a 
limited understanding of this disease and its underlying cause, which is reflected 
in the lack of an effective curative treatment for AD.
 Many of the currently developed and tested therapies are based on the 
amyloid cascade hypothesis. This hypothesis, supported by convincing genetic 
data, proposes that the extensive neuronal damage in AD is caused by increased 
concentration and aggregation of β-amyloid.(2) However, this theory does not 
offer an explanation for how this process is initiated in sporadic forms of AD, 
nor for the observation that the earliest changes in AD do not include amyloid 
deposition.3 Criticism regarding the amyloid hypothesis has fueled the 
popularity of the vascular hypothesis for AD, which states that cardiovascular 
disease is an important causal or contributing factor in sporadic AD.(4-7) 
 Although cardiovascular factors are now commonly accepted as risk factors 
for AD, the exact relationship between these factors and AD remains poorly 
understood. For example mid-life hypertension increases AD risk and anti-
hypertensive treatment potentially reduces this risk(8,9), suggesting a unidirectional, 
possibly causal relationship between hypertension and AD. However, subjects 
with a parental history of sporadic AD are more likely to have hypertension 
than control subjects(10), suggesting either a causal relationship between AD 
and hypertension or a shared causative factor. Moreover, blood pressure (BP) 
levels decline from hypertension to normotension or even to hypotension during 
the course of AD.(11) These data imply a relationship wherein AD may influence 
BP or BP may influence AD. Better understanding of the relationship between 
BP control and AD may therefore provide important new clues towards our 
understanding, and ultimately, treatment, of AD. 
 A possible link between AD and BP is the baroreflex (BR). The BR is a reflex 
loop with cardiac, vascular, and cerebral components involved in short-term BP 
regulation.(12) The BR operates via the autonomic nervous system to restore 
sudden changes in BP by changing heart rate (HR) or vascular tone. A clinical 
example is the drop in BP upon standing, which the BR corrects by a rapid 
increase in HR (parasympathetic inhibition) followed by peripheral arterial va-
soconstriction (sympathetic activation). The cholinergic system is an important 
component of cardiovascular and autonomic control, including the BR. This 
cholinergic system is prominently affected early in AD.(13,14) Therefore, we 
hypothesized that BR function is reduced early in patients with AD.(15)  
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 In this study, we further explored this hypothesis in three steps. First, we 
compared BR function between patients with AD, patients with Mild Cognitive 
Impairment (MCI) and healthy elderly subjects. Patients with MCI are thought 
to represent patients with very early-stage AD. The second step was to validate 
our findings in an independent sample of AD patients, MCI patients and elderly 
control subjects. The third and final step was to explore the role of the cholinergic 
deficit on BR function in AD, by testing the influence of cholinesterase inhibitors 
on BR function in a subgroup of patients with AD.  
Methods
Study population
Overall, this study included 34 patients with mild to moderate AD, 29 patients 
with MCI and 37 healthy control subjects in two distinct samples: (1) a derivation 
sample: 18 patients with AD (72 ± 6 years), 11 patients with MCI (71 ± 9 years), 
and 19 healthy control subjects (75 ± 3 years), recruited at Radboud University 
Nijmegen Medical Centre (RUNMC),  and (2) a validation sample: 16 AD patients 
(71 ± 8 years), 18 patients with MCI (70 ± 7 years), and 18 healthy control subjects 
(70 ± 6 years) recruited at Maastricht University Medical Center (MUMC). Data 
on cerebral hemodynamics from the RUNMC AD patients and control subjects 
and from the MUMC AD and MCI patients and control subjects have been 
published recently.(16,17) 
 In both samples, recordings of electrocardiograms (ECG) and beat-to-beat 
photoplethysmographic BP were obtained. There was a difference in body 
position during measurements between the two samples. Subjects at RUNMC 
were seated while ECG and BP were recorded, whereas the subjects at MUMC 
were supine. 
 All subjects from both centers were examined by a geriatrician, and carefully 
screened to exclude acute medical conditions. A subset of subjects (15 control 
subjects; 15 MCI patients; 29 AD patients) had an MRI scan of the brain to 
investigate medial temporal lobe atrophy (MTA). Informed consent was obtained 
from all patients and healthy control subjects before they entered the study. Both 
studies were approved by the medical ethical committees of the corresponding 
centers.
 Patients with MCI and AD were diagnosed by a multidisciplinary memory 
clinic team using the NINCDS-ADRDA criteria(18,19) and MCI consensus 
criteria(20) based on clinical evaluation and additional diagnostic tests if 
indicated, such as MRI-scan of the brain, neuropsychological testing, and 
cerebrospinal fluid analysis. In the derivation sample from RUNMC, BR in AD 
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patients was measured before and after 8 weeks of treatment with a cholinesterase 
inhibitor (galantamine,  4 weeks of 8 mg followed by 4 weeks of 16 mg). In the 
validation sample from MUMC, 10 of the 16 AD patients were already treated 
with cholinesterase inhibitors when BR was measured. 
Data acquisition and pre-processing
The ECG was recorded using a three-lead system and beat-to-beat HR was 
obtained from each R-R interval identified from the QRS complexes. Arterial BP 
was measured noninvasively at the middle finger of the right hand using 
Finapres (Finapres Medical Systems) at RUNMC and the Task Force Monitor 
(CN Systems) at MUMC, respectively. It has been shown that BP measured on 
the finger by photoplethysmography is similar to conventional auscultatory 
measurements on the upper arm.(21)  For both systems, the finger pressure cuff 
was positioned carefully at heart level with the hand being held in the left 
midaxillary line. The hand and arm were supported securely and comfortably 
with a sling. The subjects underwent several minutes of customization and the 
servo-adjust mechanism was turned off prior to recording. Periods of 100 s of 
artifact- and calibration-free data were selected by visual inspection of the time 
series of the tachogram and systogram and used for subsequent analysis. The 
time series were linearly interpolated at 1 Hz to obtain equidistant time intervals. 
The time series were detrended and filtered with an eighth-order high-pass 
Butterworth filter (0.02 Hz), to ascertain signal stationarity. 
Causal model BR estimation 
Baroreflex sensitivity (BRS) is often evaluated noninvasively by assessing 
heart-rate variability (HRV) and systolic blood pressure (SBP) variability. 
However, studies using HRV and SBP variability often report contradictory 
results.(22-24) A possible explanation for this inconsistency is that the estimation 
of the baroreflex by means of HRV assumes but not tests that the whole R-R 
interval variability is generated by SBP changes. Therefore the causal 
dependencies are not taken into account. In this study, a bivariate causal model 
(ARXAR model), which was first introduced by Nollo et al. in 2001, was used to 
quantify the BR. With this model it is possible to describe the causal relationship 
from SBP to R-R interval (the baroreflex pathway) and to separate it from the 




In short, the interactions between R-R interval and systolic blood pressure (SBP) 





According to the ARXAR model, the RR series is affected by p samples of its 
own past (by ak coefficients) and by p samples of the SBP sequence (by bk 
coefficients). The effects of other sources independent from SBP on R-R interval 
variability, considered as noise in this context, are accounted for in the model by 
means of the u(n). As outlined in Figure 1, the SBP and u signals are described 
as autoregressive processes with wsbp and wrri zero-mean input white noises.  
 The blocks C and D are formed by the autoregressive parameters of SBP and 
u, respectively. In the open loop ARXAR model the variability of SBP around its 
mean value is considered as an exogenous input, i.e. it may affect the R-R interval 
variability without itself being affected by the R-R interval variability. The 
coefficient estimation follows an iterative identification task based on the 
generalized least squares method. The model order p was chosen minimizing 
the Akaike figure of merit for the bivariate joint process |RRi SBP|.(25) The gain 
of the R-R interval – SBP transfer function (G(f)) was estimated directly from the 
coefficients of the A and B blocks. The value of the gain in the low frequency (LF) 
band (0.04 – 0.15 Hz) was considered by sampling G(f) on the LF peak of the 
spectrum of the driving SBP series.(26) It has been shown that there is a good 
agreement of the causal model with the traditional phenylephrine test to 
determine baroreceptor responsiveness.(25)
Figure 1   Bivariate autoregressive model with exogenous input (ARXAR model) for 
the description of the causal effects of SBP on R-R interval. In the open 
loop scheme, RRi values are separately determined by the exogenous 
input sbp and by sbp-unrelated variations described by the series u 
(Nollo, et al., 2001).
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Statistics
Results are presented as the mean ± standard deviation (SD) or percentage, 
unless stated otherwise. Differences in baseline variables and BR between 
control subjects and patients were evaluated with the Mann-Whitney test for 
continuous variables and chi-squared (χ2) statistics for proportions. Sensitivity 
and specificity pairs for different BR values distinguishing the groups were 
determined. These sensitivity and specificity values were used to construct a 
receiver operating characteristic (ROC) curve, in which the optimal sensitivity 





Eighteen AD patients (11 women), 19 age-matched healthy control subjects 
(5 women), and 11 MCI patients (6 women) from RUNMC participated in this 
study and had the BR measured successfully. Table 1 summarizes the sample 
characteristics. AD and control subjects did not differ with respect to SBP. 
However, SBP in MCI patients was higher than in the healthy control subjects 
(p<0.01). 
Baroreflex function
BR function was calculated in correspondence with the peak in the power 
spectra of the SBP between 0.04 and 0.15 Hz (dashed line), the frequency range 
in which BR modulation of HR occurs. 
 Mean values of the BR gain obtained by the ARXAR model are shown in 
Figure 2. BR was lower in AD (1.4 ± 0.8 ms/mmHg) compared to control subjects 
(6.4 ± 2.7 ms/mmHg) (p<0.01). BR in MCI (2.9 ± 0.7 ms/mmHg) differed from 
both AD (p<0.01) and control subjects (p<0.01) and was in between the values for 
AD and control subjects. The area under the ROC curve for the relationship 
between AD and healthy elderly was 0.92 (Figure 3). With a threshold (cut-off 
point) of 3.2 ms/mmHg for AD, sensitivity was 89% and specificity was 94%. 
Validation sample
Sample description
SBP and R-R interval data were obtained from 16 AD patients (9 women), 18 
age-matched healthy control subjects (9 women) and 18 MCI patients (10 women) 
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5(RUNMC), MCI patients had higher SBP than healthy control subjects. This was 
not the case in the validation sample from MUMC. There were additional 
differences between the derivation and validation sample: the MUMC MCI 
group had lower SBP (133 mmHg) than the RUNMC MCI group (152 mmHg) 
(p=0.02) and the MUMC control group had a lower HR (58 bpm) compared to the 
RUNMC control group (62 bpm) (p=0.04).
Baroreflex function
BR function was calculated in the same way as for the derivation sample. Mean 
values for BR gain obtained by the ARXAR model are shown in Figure 2 (dashed 
lines). Also here, BR was lower in AD (1.6 ± 1.3 ms/mmHg) compared to healthy 
control subjects (3.6 ± 0.8 ms/mmHg) (p<0.01). BR gain in the MCI group (2.3 ± 
1.4 ms/mmHg) also was lower than in healthy control subjects (p<0.01), and 
higher than AD (p=0.03). Application of the BR cut-off value of 3.2 ms/mmHg, as 
it had been obtained in the derivation sample, yielded a sensitivity of 93 % and 
a specificity of 78 % for differentiating AD from healthy control subjects in this 
validation dataset (Table 2).
Figure 2   BR values in mean ± standard deviation for the three groups (MCI patients, 
patients with AD and healthy age-matched control subjects) 
The solid lines represent the derivation sample and the dashed lines represent the validation sample. 
Significant differences are indicated by the connecting lines (dashed for data of the derivation 




In eighteen AD patients (11 women) in the derivation sample, SBP and R-R 
interval data were obtained before and after treatment with cholinesterase 
inhibitors. Following treatment with cholinesterase inhibitors,  BR increased 
from 1.4 ± 0.8 ms/mmHg to 2.4 ± 0.9 ms/mmHg (p<0.01). In the validation 
Figure 3   ROC curve analysis of the predictive value of BR in distinguishing AD 
patients from healthy control subjects 
The area under the curve equals 0.92; 95% confidence interval is 0.84-1.00; p-value < 0.01. The square 
shows the optimal BR cut-off point  at 3.2 ms/mmHg resulting in a sensitivity of 89% and a specificity 
of 94% is reached.
Table 2   Performance of the proposed baroreflex cut-off score
Baroreflex value n of patients 
(% of total)
AD Control sensitivity specificity
≤ 3,2 ms/mmHg 18 (51 %) 14 4 93% 78%
> 3,2 ms/mmHg 17 (49 %) 1 14
Performance of the proposed baroreflex cut-off score to distinguish between AD and healthy control 
subjects, in the validation sample.
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sample, no before-after cholinesterase-inhibitor treatment comparisons were 
available, however in this sample,  BR was  higher in  the 10 patients who were 
treated with cholinesterase inhibitors (2.0 ± 1.5 ms/mmHg) compared with the 6 
patients without. (0.89 ± 0.4 ms/mmHg) (p=0.02). Cholinesterase-inhibitor-treat-
ed patients in  the derivation sample had a slightly higher BR than those  in  the 
validation sample (p=0.03). 
Discussion
The main finding of our study is that the BR function is lowered in patients with 
AD compared to age-matched control subjects. Our results are in agreement 
with the depressed BR sensitivity observed in 24 patients with AD.(27) Our 
study adds to these observations by the addition of a group of patients with 
MCI, reflecting early-stage AD, by reproducing our findings in an independent 
sample, and by investigating the effect of cholinesterase inhibitors on BR. 
Furthermore, a more precise BR quantification method was used. The traditional 
sequence analysis used in the study of Szili-Törok et al.(27) assumes, but not 
tests, that the whole R-R interval variability is generated by SBP changes. The 
method used in our study takes this causal dependency into account by dividing 
the R-R interval variability in SBP-related and SBP-unrelated parts. 
 The difference in BR function was so prominent that it was possible to 
distinguish patients with AD from control subjects by their BR function. The 
discriminatory value of BR was so strong that it achieved a performance that 
compares with or even exceeds that of current diagnostic biomarkers, such as 
cerebrospinal fluid analysis of amyloid β42. Indeed, a cut-off value for BR gain 
of 3.2 ms/mmHg reached a sensitivity of 89% and a specificity of 94% to 
discriminate AD from control subjects in the derivation sample. For comparison, 
cerebrospinal fluid analysis of amyloid β42 has an ROC of 0.9, with a sensitivity 
of 93% and a specificity of 87% to discriminate AD from control subjects.(28) 
This discrimatory cut-off value for BR performed equally well in the independent 
validation sample with a sensitivity of 93% and a specificity of 78% for differentiating 
AD from healthy control subjects. Additionally, MCI patients had a BR value 
that was intermediate between control subjects and AD. A strength of our study 
is that also these results were confirmed in the independent validation sample. 
 These findings underscore the importance to explore the underlying 
mechanism that explains this association between impaired BR functioning and 
AD. They raise the question whether AD pathology results in impaired BR 
functioning or whether impaired BR functioning contributes to (acceleration of) 
AD pathology.  
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Possible mechanism and consequence of the decreased BR in AD
The BR is the major feedback control system for BP. Primary afferent fibres from 
arterial baroreceptors - in the carotid sinus and aortic arch - send information to 
the nucleus tractus solitarius in the medulla oblongata.(29) From here, 
information is sent via interneurons to the hypothalamus or to higher regions in 
the brainstem and forebrain(30), including the insular cortex.(31) The insular 
cortex is a recognized site of autonomic cardiovascular control and baroreflex-
mediated autonomic cardiovascular function.(32) In 1998, Braak et al.(33) 
demonstrated a hierarchical progression of AD pathology that includes the 
insular cortex in an early stage. This insular involvement may lead to changes in 
cardiovascular and autonomic control, and may consequently affect the BR.
(32,34)
 Further circumstantial evidence is found in the effects of exercise. Exercise 
improves cardiovascular function and BR.(35) Exercise has also been shown to 
lower the risk of AD.(36) Although direct associations between exercise, BR and 
AD risk have not been investigated, and BR could be no more than a marker of 
exercise, it can be hypothesized that BR function is part of the causal pathway 
that links exercise to reduced AD risk, or that augmented BR is a marker of 
beneficial effects of exercise on autonomic brain centers. 
 Here, we have also shown that treatment with cholinesterase inhibitors 
augmented BR function in AD. This is in line with recent findings that atropine, 
in a dose which augments vagal tone, increased cardiovagal baroreflex gain in 
older subjects.(37) Our findings cannot be explained by age-related effects 
only(38) because we compared AD and MCI patients with age-matched healthy 
control subjects. Cholinesterase inhibitors partly compensate for the cholinergic 
deficit in AD. The cholinergic system has a pivotal role in learning and memory.
(39) However, the augmented BR function suggests that cholinesterase inhibitors 
may slow clinical disease progression not only through direct cognitive effects 
but also through their influence on cardiovascular factors such as BP regulation. 
Our findings may extend to preclinical and early clinical AD, for example 
patients with MCI. Patients with MCI have a high risk of progression to dementia, 
particularly of the Alzheimer type.(20,40) There is a greater orthostatic fall in 
SBP in MCI and Alzheimer patients than in control subjects(22,23) and the 
prevalence of orthostatic hypotension in MCI patients lies between control 
subjects and AD patients.(41) This observation parallels the BR values in control 
subjects, MCI and AD found in our study and is in line with an earlier study 
which showed an association between blunted baroreflex functioning and 
increased risk of orthostatic hypotension.(42) 
 Despite the fact that several studies have shown an association between AD 
and autonomic instability, such as increased pupillary dilatation(43), diminished 
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HR variability(44), and orthostasis, the significance of the abnormalities in BR 
among AD patients is not yet fully known. However, impaired BR in other 
common dementia subtypes, such as Parkinson’s disease and Lewy Body 
Disease, is held partly responsible for the higher prevalence of orthostatic 
hypotension(22) and increased cardiovascular mortality. These patients also 
exhibit a significant loss of cholinergic forebrain neurons.(45)
BR functioning as diagnostic tool
In the perspective of new therapeutic options to slow the progression of 
dementia, an early diagnosis of AD is of utmost importance because all treatment 
strategies are more effective in the earlier phases of the disease.(46) In this study, 
a rapid, noninvasive, and inexpensive procedure without need for active patient 
cooperation was used to estimate BR function from ECG and BP recordings, 
obtained when the patient quietly sits or lies down. Our results show that in 
patients with AD, a lowered BR could be a sensitive and specific marker of the 
disease. A strength of the study is the consistent decrease in BR found over the 
different groups (from healthy subjects to MCI patients to AD patients). This 
result points towards a disease-specific involvement of the BR. However, 
although we have shown that BR discriminates between AD and control 
subjects, further evidence must be obtained for its discriminatory value against 
important differential diagnoses in memory clinics, i.e. other causes of dementia 
and depression.    
Limitations
Some methodological issues need to be considered. First of all, the diagnosis of 
AD and MCI in our study remains a clinical one. There was no pathological 
confirmation of the underlying disease. However, previous studies have shown 
that a clinical diagnosis is only inaccurate, compared to pathological diagnosis, 
in about 11% of mild cases.(47) The patients with MCI and AD were diagnosed 
by a multidisciplinary memory clinic team consisting of several geriatricians, 
neuropsychologists, occupational therapists and speech therapists. Lewy body 
dementia and vascular dementia were excluded based on diagnostic criteria for 
these conditions, using information obtained by means of history, clinical 
examination, laboratory tests and additional, mostly radiological, investigations. 
In a population referred to a memory clinic (as in this study), depending on 
criteria, a high percentage of MCI patients will develop AD.(48,49) Still, in some 
patients MCI remains stable and never progresses to AD. Therefore the 
assumption that abnormal BR function serves as early detection of the Alzheimer 
disease process remains hypothetical. To overcome this limitation, larger scale 
studies with follow-up of MCI and AD patients are needed, with observations of 
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BR during the different stages of progression of AD. Maybe a combination with 
other easy to determine parameters, in particular the cerebrovascular resistance 
index(16), could enhance discrimination of patients at risk for developing AD. 
 Secondly, it may be argued that results should have been corrected for 
differences in use of medication, since we included patients with co morbidities 
and medication. There is some information about whether commonly used anti-
hypertensives, such as metoprolol and enalapril, can augment the cardiac 
autonomic function in hypertensive patients. Keeley et al. showed that 
beta-blockers can directly improve cardiovascular autonomic regulation in 
normotensive and hypertensive patients.(50) Further, Mancia et al. showed an 
increase in BR function when the circulating levels of angiotensin II and 
aldosterone were reduced by angiotensin-converting enzyme (ACE) inhibitors.
(51) Because antihypertensive drugs mostly show an increase of the BR function, 
we argue that the difference in BR function between AD patients and healthy 
elderly would have been even greater when the AD patients had used no antihy-
pertensives. 
 Thirdly, some differences exist in population and protocol characteristics 
between the derivation and validation sample. In the validation sample the 
control subjects had a higher SBP (136 mmHg compared to 125 mmHg) than in 
the derivation sample. Furthermore, in the derivation sample BP and HR were 
obtained in the sitting position, in the validation sample BP and HR were 
obtained supine. These differences may explain the difference in BR between 
the two control groups (6.4 ms/mmHg in the derivation sample versus 3.6 ms/
mmHg in the validation sample). Bristow et al. showed an inverse relationship 
between resting mean BP and BR, with reduced BR sensitivity in hypertension.
(52) This might explain the observed lower BR in the derivation sample where 
the SBP was higher. However, literature yields discordant results about the 
influence of posture on the BR results.(53,54) 
 Finally, a limitation of the study is the cross sectional design. This design 
allows us to establish the relationship between BR and AD, but we are unable to 
establish whether the impaired functioning of the BR is the effect or the cause of 
neurodegeneration.
Conclusions
This study shows a strong association between AD and diminished BR function. 
A possible link is the cholinergic system which is involved in both BR and AD. 
Cholinesterase inhibitors increase BR function in AD. Furthermore, MCI patients 
have an intermediate BR function between the normal and the AD subjects. 
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Considering this, it is possible that  early in AD besides cognition also BP 
regulation is affected. Further research on the relationship between BR and AD 
might provide valuable insights into the pathophysiology and for the diagnosis 
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BLOOD PRESSURE VARIABILITY AND CEREBROVASCULAR DISEASE
5
To the Editor: With interest we have read the article by White et al.(1) In their 
well-designed prospective cohort study, they demonstrate the importance of 
increased 24-hour systolic blood pressure, but not clinic systolic blood pressure, 
in the progression of brain white matter hyperintensity volume burden 
associated with impairment of cognitive function in older people. They conclude 
that 24-hour of systolic blood pressure may be a potential target for intervention 
in the elderly to reduce vascular disease of the brain and impairment of function. 
Unfortunately, they did not take blood pressure variability into account , and 
they did not measure small-vessel disease more precisely with diffusion 
tensor-imaging measures. Visit-to-visit variability in systolic blood pressure is a 
strong predictor of stroke, independent of mean systolic blood pressure.(2) Even 
in patients with treated hypertension, an increased residual variability in 
systolic blood pressure is associated with a high risk of vascular events.(2) 
However, stroke has a different pathophysiology compared to small-vessel 
disease that is reflected in white matter intensity lesions. Moreover, visit-to-visit 
blood pressure variability does not reflect the same regulatory mechanisms as 
regular blood pressure measurement with a 24-hour ambulatory blood pressure 
monitoring device. Nevertheless, in a small sample of 39 older adults with 
cardiovascular disease, in whom blood pressure was measured using an 
automated monitor every 10 minutes for 2 hours, systolic blood pressure 
variability was associated with white matter hyperintensities.(3) Therefore, 
blood pressure variability, but also blood pressure instability (like orthostatic 
hypotension), might provide additional information on the association between 
blood pressure and the presence of small-vessel disease. 
 Next, small-vessel disease was only measured by conventional magnetic 
resonance imaging measurement of white matter hyperintensity volume. 
Diffusion tension imaging has been shown to be of added value in explaining 
cognitive function based on brain imaging.(4) This is explained by the fact that 
small-vessel disease is already causing microstructural damage in the white 
matter, even on strategic places, which can be measured by diffusion tension 
imaging but are still missed by focusing on white matter hyperintensities.
 In conclusion, White et al.(1) provide convincing evidence for the association 
between 24-hour systolic blood pressure and white matter hyperintensities. 
However, when blood pressure variability is added to the usual static systolic 
blood pressure in their analysis, it might potentially further refine and optimize 
the target for intervention in the elderly to reduce vascular disease of the brain 
and impairment of function.(5) Therapeutic effects of blood pressure treatment 
probably are best followed by serial diffusion tension imaging measurements, 
as diffusion tension imaging measures are a better reflection of early changes in 
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In Alzheimer’s Disease (AD) cerebrovascular function is at risk. Transcranial In 
Alzheimer’s Disease (AD) cerebrovascular function is at risk. Transcranial 
Doppler, near-infrared spectroscopy, and photoplethysmography are 
non-invasive methods to continuously measure changes in cerebral blood flow 
velocity (CBFV), cerebral cortical oxygenated haemoglobin (O2Hb), and blood 
pressure (BP). In 21 patients with mild to moderate AD and 20 age-matched 
controls, we investigated how oscillations in CBFV and O2Hb are associated 
with spontaneous and induced oscillations in BP at the very low (VLF = 0.05 Hz) 
and  low frequencies (LF = 0.1 Hz). We applied spectral and transfer function 
analysis to quantify dynamic cerebral autoregulation and brain tissue 
oxygenation. In AD, cerebrovascular resistance was substantially higher (34 %, 
AD vs. control: ∆ = 0.69 (0.25) mmHg/cm/s, p = 0.012) and the transmission of 
VLF cerebral blood flow (CBF) oscillations into O2Hb differed, with increased 
phase lag and gain (Δ phase 0.32 (0.15) rad; Δ gain  0.049 (0.014) µmol/cm/s, p 
both < 0.05). The altered transfer of CBF to cortical oxygenation in AD indicates 
that properties of the cerebral microvasculature are changed in this disease.   
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Introduction
In patients with Alzheimer’s disease (AD) and in mouse models of AD, the structural 
integrity of the cerebral vasculature, especially of cortical microvessels, is markedly 
compromised.(1) Additionally, dynamic cerebral autoregulation, the vascular 
mechanism which aims to stabilize brain perfusion, is impaired in mouse models of 
AD.(2,3) Whether dynamic cerebral autoregulation is also altered in human AD 
remains unknown. Recently, we have shown that patients with early stage AD have 
a reduced cerebral blood flow velocity (CBFV) and an increased cerebrovascular 
resistance (CVR) compared to age-matched healthy controls. Moreover, AD patients 
had smaller spontaneous cerebral blood flow (CBF) oscillations, relative to blood 
pressure (BP) oscillations. This implies a reduction in transfer function gain, a 
parameter that quantifies dynamic cerebral autoregulation and describes how 
changes in BP are transferred to changes in CBFV.(4) Notably, changes in CBFV were 
measured using transcranial Doppler (TCD) in the middle cerebral artery (MCA), 
reflecting global changes in cerebral blood flow (CBF) but not necessarily changes 
that occur at brain tissue level.(5)
 Near-infrared spectroscopy (NIRS) and functional MRI have revealed 
spontaneous oscillatory changes in cerebral cortical oxygenation.(6) These oscillations 
appear similar to those observed in CBFV and BP.(7) However, the exact characteris-
tics of the relationship between dynamic changes in CBFV measured in the basal 
cerebral arteries and brain tissue oxygenation remains unknown. It is possible that 
oscillations in brain tissue oxygenation are induced by changes in global CBF and 
that the dynamic relationship between these variables reflects not only the function 
of the cerebral vasculature to deliver oxygen to the brain tissue, but also brain tissue 
oxidative metabolism.(8) We hypothesized that the presence of vascular abnormalities 
in AD may alter this dynamic relationship between CBF and brain tissue oxygenation. 
In this article we focus on the two different but dependent dynamic relationships, 
the relation between BP and CBF on the one hand and the relation between CBF and 
cerebral cortical oxygenation on the other.   
 Cerebral blood flow velocity in the middle cerebral artery changes 
dramatically if large changes in BP are induced by changes in body posture 
from sitting or squatting to upright standing.(9,10) This provides a model to 
study not only the relationship between BP and CBF, but also between CBF and 
cerebral cortical oxygenation. The aim of this study was to test the hypothesis 
that oscillations in BP and CBF, associated with changes in body posture, are 
transmitted into changes in brain cortical oxygenation and that this dynamic 
relationship is altered in patients with mild to moderate AD. 
 For this purpose, beat-to-beat changes in BP, CBFV, and concentrations of 
frontal cortical oxyheamoglobin (O2Hb)] and deoxy-heamoglobin (HHb) were 
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measured continuously using finger arterial BP measurements, TCD and NIRS, 
during repeated sit-stand maneuvers in patients with newly diagnosed AD. 
Fourier spectral and transfer function analysis were used to quantify the 
magnitude of oscillations and the dynamic relations between these variables. 
The repeated sit-stand maneuvers were performed to augment the spontaneous 
BP and CBFV oscillations.(10) They induce large oscillations in BP, CBFV, and 
O2Hb and enhance the coherence between these variables (> 0.4) and therefore 
improve the reliability of the transfer function analysis.(5) The repeated sit-stand 
maneuvers were performed at 0.05 and 0.1 Hz. At the very low frequency (0.05 
Hz) dynamic cerebral autoregulation is active, but in the low frequency (0.1 Hz) 
dynamic cerebral autoregulation is less active.(11)
Methods
Subjects
We recruited 21 AD patients, aged 65 years and older. All patients had been 
newly diagnosed with AD in the memory clinic at Radboud University Nijmegen 
Medical Centre. Patients were diagnosed with mild or moderate AD according 
to the criteria of the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA), Clinical Dementia Rating (CDR)  0.5 – 2.(12) 
They were not yet treated with cholinesterase inhibitors. As a control group, 20 
age-matched healthy old persons were selected from a group of volunteers that 
responded to a newspaper advertisement. All patients and volunteers were 
carefully examined by a geriatrician, including physical examination, laboratory 
evaluation, CT (n = 2) or MRI-scan (n =39) of the brain, and neuropsychological 
testing. All controls and randomly selected patients (n = 10), underwent a 
Doppler study of the carotid and vertebral arteries to rule out significant stenosis 
(> 50 %). 
 The study was approved by the Ethics Committee for Research on Human 
Subjects, Radboud University Nijmegen Medical Centre, and all volunteers and 
primary caregivers of the AD patients gave written informed consent, and AD 
patients themselves gave verbal consent.
CBFV and NIRS measurements 
Using TCD, CBFV was measured in the MCA. Changes in CBFV represent 
changes in flow, under the assumption that the diameter of the insonated vessel 
remains constant. The MCA is one of the major conduit arteries of the cerebral 
circulation and branches directly from the common carotid artery. Many studies 
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have demonstrated that the diameter of the MCA does not  change appreciably 
even during moderate alterations in BP and end-tidal CO2.(13-15) Therefore, 
changes in CBFV should represent predominately changes in CBF in this study. 
Further it was assumed that there is no displacement of the MCA with respect 
to the probe position during repetitive vertical postural changes.(9)  
 NIRS measures cerebral cortical changes in O2Hb and HHb. The basic 
principle of NIRS is that near-infrared light penetrates the skull and brain, and 
is absorbed by the chromophores O2Hb and HHb, that have different absorption 
spectra. Assuming constant scattering, changes in concentration of these 
chromophores can be deduced, using the modified Lambert-Beer Law.(16,17) 
The measurements lump all haemoglobin concentration change from a volume 
of brain under the optodes. This volume might include all types of vessels. 
However, the actual vessel volume within the examined tissue is very small, 
and contribution of hemoglobin in conduit vessels to the NIRS signal are 
negligible. Total Hb (THb), the sum of O2Hb and HHb, is associated with local 
cerebral blood volume, whereas O2Hb is associated with local cerebral blood flow.(7) 
 We applied a continuous-wave NIRS device with 3 light bundles with 
wavelengths of 775 nm, 845 nm, and 904 nm (Oxymon, Artinis Medical 
Systems™, Zetten, The Netherlands). A fixed differential path length factor 
(DPF) of 6.6 (corresponding to age 50) was used in all subjects, which accounts 
for the increased distance travelled by light due to scattering.(16) At present, no 
data are available on the actual variation of the DPF with age above 50 years. 
Our control and patient group, however, were age-matched, which should 
reduce any systemic measurement bias induced by using a fixed DPF.
Data Acquisition 
Subjects were in sitting position and received first a three-lead ECG for 
measurement of the interval between consecutive R-peaks (RR interval). BP was 
measured using a photoplethysmography cuff on the index or middle finger of 
the left hand (Finometer, Finapres Medical Systems, Amsterdam, the 
Netherlands), with the hand resting approximately at heart level supported by a 
sling. Data were collected by the Finometer for an uninterrupted period which 
lasted for a maximum of 5 minutes. Transcranial Doppler ultrasonography was 
used to measure CBFV. The left and right middle cerebral artery were insonated 
by placing a 2-MHz Doppler probe (Multi-Dop, Compumedics DWL, Singen, 
Germany) over the temporal window. The middle cerebral arteries were 
identified according to their signal depth, velocity, and wave characteristics.(18) 
If only one signal was available due to one-sided temporal window failure, we 
included this available signal for analysis. The probes were locked at a constant 
angle and position during data collection with a customized headband (Spencer 
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technologies, Seattle, WA, USA). Two pairs of NIRS optodes were placed and 
tightly fixed over the left and right frontal cortex in the same headband that 
locked the Doppler probes The midpoint between the horizontally positioned 
pairs was Fp1 for the left pair and Fp2 for the right pair, according to the 
international 10-20 electrode system. An interoptode distance of 5.0 cm was 
used to minimize contamination from the extra-cerebral circulation and to 
maximize the signal intensity.(16) NIRS cables and optodes were tightly fixed to 
prevent movement artifacts. Arterial saturation (SaO2) was recorded with a 
pulse oxymeter and end tidal CO2 (EtCO2) using a capnograph (N1000, Nellcor, 
Boulder, CO, USA). All data were sampled at 125 Hz. 
Protocol 
From twelve hours before the study, subjects refrained from caffeinated 
beverages and alcohol. They had a light breakfast at least two hours before the 
visit.  All experiments were performed in the morning, in a quiet environmen-
tally-controlled laboratory. After at least 30 minutes of sitting rest, spontaneous 
oscillations data were collected for 5 minutes. To assess the dynamic 
pressure-flow as well as the flow-brain tissue oxygenation relationship, 
spontaneous BP and CBFV oscillations were augmented using repeated sit-stand 
maneuvers at two different frequencies.(10) Subjects were instructed to perform 
repeated sit-stand maneuvers at 0.05 Hz (10 s sit followed by 10 s stand) for 5 
minutes and at 0.1 Hz (5 s sit followed by 5 s stand) for 4 minutes. Verbal signs 
were given to facilitate repeated changes in body posture. The maneuvers were 
separated by 10 minutes for recovery. 
Data Processing
All data were simultaneously recorded for offline analysis (Oxysoft, Artinis 
Medical Systems). A running average filter of 1 s was applied to the O2Hb and 
HHb signals to increase the signal to noise ratio, and to reduce the heart beat 
and high frequency noise.(16,17)  
 Spectral analysis was performed on beat-to-beat mean BP, CBFV, O2Hb, and 
HHb changes. The signals were aligned with the time of the R wave peaks of the 
ECG. The time series were then linearly interpolated at 2 Hz to obtain equidistant 
time intervals and detrended with third-order polynomial fitting. These data 
then were subdivided into 128 segments with 50% overlap and a Hanning-window 
was applied for spectral estimation. These data segmentations are based on a 
trade-off between a reduction in spectral variance and keeping sufficient 
spectral resolution. Each Hanning-windowed segment was fast-Fourier 
transformed and the periodograms were averaged to calculate the autospectrum 
of BP, CBFV, O2Hb and HHb.(11)
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 For spectral analysis the following frequency ranges were chosen: the very 
low frequency (VLF) range: 0.02 – 0.07 Hz for spontaneous oscillations and for 
the induced 0.05 Hz maneuver, and the low frequency (LF) range: 0.07 – 0.13 Hz 
for spontaneous oscillations and for the 0.1 Hz maneuver.(10) Spectral power of 
oscillations was calculated as area under the curve (AUC) of the power spectral 
density plots. For comparisons, power spectral density plots of BP, CBFV, O2Hb, 
and HHb were included if data on all signals were available for sitting rest and 
during both repeated sit-stand maneuvers. 
 The dynamic relation between BP as input and CBFV as output (BP – CBFV) 
and the dynamic relation between CBFV as input and O2Hb as output (CBFV – 
O2Hb) were determined with transfer function analysis during the repeated 
sit-stand maneuvers. Because of low coherence we did not include the calculation 
of transfer function during spontaneous oscillations of the above dynamic 
relationships and between CBFV as input and HHb as output (CBFV-HHb) 
during spontaneous and induced oscillations. Mean values of phase, gain, and 
coherence of the transfer function were analyzed in the same VLF and LF as 
described above. We have previously described the explanation of these 
estimates in detail.(5,9,10) In short, the phase shift quantifies the displacement in 
time of a signal relative to another. The transfer function gain determines the 
magnitude relationship between two signals. Coherence tests the linearity of 
the relationship between these signals. Coherence approaching unity in a 
specific frequency suggests a linear relationship, whereas coherence approaching 
zero indicates no relationship between the signals, severe extraneous noise, or a 
non-linear relationship.(19) A coherence of 0.4 is considered the lower limit 
where transfer function estimates can be calculated with confidence.(11) 
Estimates of phase, gain, and coherence were therefore only included if 
coherence was > 0.4. All analyses were performed with commercially available 
software (DADiSP, DSP Development, Cambridge, MA, USA).
Statistical Analysis 
Data are presented as mean ± SD. Normal distribution was tested using Q-Q 
plots and could not be assumed for power spectral data of beat-to-beat mean BP, 
CBFV, 02Hb and HHb. Comparisons between the control and patient group 
were made using the independent samples t test and the Mann-Whitney’s U test. 
For the comparisons of the transfer function estimates between both 0.05 Hz 
and 0.1 Hz maneuvers, a paired samples t test was applied. Statistical significance 
was set at p < 0.05. All statistical analysis were performed using statistical 





Table 1 presents the baseline characteristics of patients and controls at screening. 
Patients and controls were matched for age and blood pressure level at screening 
(Table 1). Specifically, 15 out of 21 AD patients and 14 out of 20 controls were 
hypertensive (BP > 140/90) at screening. More AD patients however, used anti-
hypertensive medication (12 vs. 4) and 5 AD patients had diabetes mellitus type 
2. As expected, patients had substantially lower cognitive tests scores and more 
hippocampal atrophy. The difference in age-related white matter score was not 
significant (Δ 1.9 on the 30 point scale, p = 0.089).
  
Baseline Hemodynamic Measurements
Table 2 provides an overview of the baseline hemodynamics under resting 
conditions. Heart rate (HR) and BP data could be obtained in all controls and 
patients. In 1 control and 4 AD patients, data on CBFV could not be obtained due 
to an insufficient temporal window. Additionally, in 1 AD patient the NIRS 
measurement had to be excluded because of a low signal-to-noise ratio. Although 
systolic and diastolic BP (sphygmomanometry) were comparable between AD and 
controls at screening, mean arterial pressure as obtained from the average of 5 
min recording at rest using Finometer was higher in AD. Moreover, resting heart 
rate and spontaneous BP oscillations at the LF range of 0.1 Hz  were higher in AD.
 In patients with AD, despite the higher BP, CBFV was reduced by 10 % 
compared to controls. Consistently, there was a 34 % increase in cerebrovascular 
resistance index in AD (difference = 0.69 (0.25) mmHg/cm/s, p = 0.012) (Table 2). 
Alzheimer patients also had larger spontaneous oscillations in CBFV and O2Hb 
at the LF range (Table 2). 
Repeated Sit-Stand Maneuvers
Representative changes in BP, CBFV, and O2Hb and HHb during baseline, and 
the 0.05 Hz and 0.1 Hz sit-stand maneuvers, are presented in Figure 1. Note that, 
as expected, O2Hb and HHb oscillate in counter-phase, and further that these 
oscillations appear clearly related to the oscillations in BP and CBFV. Figure 2 
shows the group averaged power spectra of controls and AD. The repeated 
sit-stand maneuvers induced oscillations in all signals (BP, CBFV, O2Hb, and 
HHb), and the spectral power of these oscillations was significantly larger than 
for spontaneous oscillations in the corresponding frequency range (Figure 2). 
Notably, the 0.05 Hz repeated maneuver induced the most powerful oscillations. 
Power spectra for BP, CBFV, O2Hb, and HHb were similar in AD and controls in 
the VLF and LF range (Table 3). 
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 Figure 3 provides an example of the relation between the oscillations in BP 
and CBFV, and of the oscillations between CBFV and O2Hb during 0.05Hz 
sit-stand maneuvers. During the maneuvers, oscillations in CBFV lead those of 
BP, whereas oscillations in O2Hb follow those of CBFV (phase lag), suggesting a 
time delay between changes in CBF and brain tissue oxygenation.  
Table 1   Baseline Characteristics of Healthy Controls and Alzheimer’s Patients
 
Healthy Controls Alzheimer patients 
Age (years) 74.5 (2.8) 72.3 (5.7)
Gender  (male : female) 14 : 6 9 : 12
BMI (kg/m2) 24.8 (2.5) 24.5 (3.1)
BP sys (mmHg) 148.3 (20.0) 150.5 (18.9)
BP dias (mmHg) 83.3 (8.9) 80.1 (9.7)
CDR (range) 0 1.0 (0.5 – 2.0)
MMSE 29.3 (1.2) 21.3 (4.7) *
CamCog NA 67.4 (13.4)
Use of antihypertensive medication N = 4 N = 12** 
Antihypertensive medication
   Diuretic 3 5
   ACE Inhibitor - 4
   CA-Channel Blocker - 2
   Βeta Blocker 2 7
   AT  II Antagonist - 1
Smoking N = 3 N = 2
Diabetes (Type 2) N= 0 N = 5**
MRI 
   MTA 0.44 (0.61) 2.00 (0.80)*
   ARWMC 3.35 (3.12) 5.25 (3.09)
Values are presented as mean, with standard deviation in parentheses; CDR is presented as mean 
and range because the score is an ordinal value. BP was measured with sphygmomanometry at 
screening. MTA score 37, range 0–4; ARWMC score 38, range 0–30.
Key: ACE, angiotenstin converting enzyme; ARWMC, age-related white matter changes; AT II, 
angiotensin II; BMI, body mass index calculated as weight (kg) divided by height (m2); BP, blood 
pressure; CA, calcium; CamCog, cognitive and self-contained part of the Cambridge Examination 
for Mental Disorders of the Elderly; CDR, clinical dementia rating; dias, diastolic; MMSE, Mini 
Mental State Examination; MRI, magnetic resonance imaging; MTA medial temporal lobe atrophy; 
NA, not applicable; sys, systolic.
* p < 0.001, ** p < 0.05.
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 No differences in transfer function gain and phase between BP and CBFV 
were observed between the controls and AD (Table 3). Transfer function gain 
between CBFV and O2Hb was higher in AD during the 0.05 Hz repeated sit-stand 
maneuver, and the phase lag between CBFV and O2Hb was larger (Table 3 and 
Figure 4). The use of antihypertensive medication in the control and AD group 
did not lead to within-group differences in gain and phase between CBFV and 
O2Hb (p all > 0.1). The within-group differences for diabetes mellitus in the AD 
group could not be assessed, because 3 diabetic patients were excluded from 
transfer function analysis due to low coherence (that is, ultimately, only 2 
patients with (type II) diabetes were included in the AD group for this part of 
the analysis).  
Table 2   Baseline Hemodynamics in healthy controls and Alzheimer patients
Healthy Controls Alzheimer patients 
Mean HR (bpm) 61.3 (5.8) 69.7 (11.8)* 
Mean  BP (mmHg) 78.8 (10.4) 87.6 (18.8)*
Mean CBFV (cm/s) 42.1 (9.9) 37.7 (14.7)
CVRi (mmHg/cm/s) 2.00 (0.55) 2.68 (0.97)* 
PetCO2 (mmHg) 34.7 (3.1) 35.2 (2.5)
BP VLF (mmHg2) 4.62 (1.8) 7.42(4.8)
BP LF (mmHg2) 1.19 (0.6) 2.29 (1.8)*
CBFV VLF ((cm/s)2) 2.43 (1.3) 3.49 (1.3)
CBFV LF ((cm/s)2) 0.55 (0.3) 1.29 (1.0)*
[oxyHb] VLF ((μmol/l)2) .038 (0.012) 0.084 (0.1)
[oxyHb] LF ((μmol/l)2) 0.0091 (0.006) 0.037 (0.08)*
[HHb] VLF ((μmol/l)2) 0.016 (0.009) 0.036 (0.05) 
[HHb] LF ((μmol/l)2) 0.0036 (0.003) 0.011 (0.02)
Average of 5 minutes measurement during sitting rest. For CBFV either the average of left and right, 
or the available signal were included for analysis. Values are presented as mean, with standard 
deviation in parentheses. oxyHb and HHb denote changes in concentration of frontal cortical 
oxygenated and deoxygenated hemoglobin, respectively. BP VLF, BP LF, CBFV VLF, CBFV LF, oxyHb 
VLF, oxyHb LF, HHb VLF, and HHb LF, spectral power of BP, CBFV, oxyHb and HHb in the very low 
frequency and low frequency range (VLF, 0.02– 0.07 Hz; LF, 0.07– 0.13 Hz). 
Key: BP, blood pressure; CBFV, cerebral blood flow velocity; CVRi, cerebrovascular resistance index 
(mean BP/CBFV); HHb, deoxygenated hemoglobin; HR, heart rate; LF, low frequency; oxyHb, 
oxygenated hemoglobin; PetCO2, pressure of end-tidal CO2; VLF, very low frequency.
* p < 0.05.
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Figure 1   Example of blood pressure, cerebral blood flow velocity, and cortical 
frontal oxy- and deoxygenated hemoglobin oscillations in sitting rest and 
during the 0.05 Hz and 0.1 Hz repeated sit-stand maneuvers in 1 subject 
Beat-to-beat data from 1 subject, variability in blood pressure (BP; upper panel), cerebral blood flow 
velocity (CBFV; middle panel) in the left middle cerebral artery, left frontal cortical oxygenated and 
deoxygenated hemoglobin (O2Hb, solid line, and HHb, dashed line—both bottom panel), during 
baseline measurements in sitting rest (left panel) and the repeated sit-stand maneuvers at 0.05 Hz 
(middle panel) and 0.1 Hz (right panel). Note the enhanced amplitude and consistency of the 
oscillations induced by the 0.05 Hz repeated sit-stand maneuvers. 
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Figure 2   Group averaged power spectra of blood pressure, cerebral blood flow 
velocity, and cortical frontal oxy- and deoxygenated hemoglobin 
oscillations in sitting rest and during repeated sit-stand maneuvers 
Results of spectral analysis of blood pressure (BP; upper panel), cerebral blood flow velocity (CBFV; 
middle panel), and frontal cortical oxygenated and deoxygenated hemoglobin (O2Hb, black line, and 
HHb, gray line — both bottom panel) during sitting rest (left), the 0.05 Hz repeated sit-stand 
maneuver (middle), and the 0.1 Hz repeated sit-stand maneuver (right). The solid lines represent the 
spectra of the oscillations in healthy controls, the dotted lines are for the Alzheimer’s patients.
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Table 3   Hemodynamics in healthy controls and Alzheimer patients during two 
repeated sit-stand maneuvers
Healthy Controls Alzheimer Patients
0.05 Hz 0.1 Hz 0.05 Hz 0.1 Hz
Number of Subjects+ 16 17 15 15
HR (bpm) 68.18 (7.3) 73.50 (7.0) 79.21 (13.5)* 85.45 (14.5)*
BP  (mmHg) 91.27 (14.7) 93.05 (13.5) 105.64 (21.1)** 104.84 (21.5)
CBFV (cm/s) 46.43 (7.9) 46.45 (7.5) 40.79 (14.8) 43.53 (14.8)
PetCO2 (mmHg) 34.23 (2.5) 34.24 (2.2) 34.01 (2.7) 33.8 (2.4)
PS BP (mmHg2) 42.89 (19.1) 15.24 (7.19) 38.36 (26.0) 17.49 (13.8)
PS CBFV ((cm/s)2) 17.28 (9.8) 7.63 (4.2) 18.72 (17.7) 8.24 (5.8)
PS OxyHb ((μmol/L)2) 0.15 (0.08) 0.058 (0.047) 0.29 (0.2) 0.11 (0.16)
PS HHb ((μmol/L)2) 0.10 (0.09) 0.036 (0.043) 0.12 (0.09) 0.043 (0.054)
TFA BP – CBFV++ 
Number of Subjects 16 18 13 15
Phase  (rad) 0.73 (0.29) 0.70 (0.23) 0.81 (0.24) 0.65 (0.21)
Gain (cm/s/mmHg) 0.55 (0.16) 0.60 (0.13) 0.47 (0.17) 0.62 (0.22)
 nGain (%cm/s/%mmHg) 1.18 (0.29) 1.36 (0.25) 1.25 (0.30) 1.43 (0.31)
Coherence  0.65 (0.12) 0.76 (0.13) 0.68 (0.11) 0.77 (0.10)
TFA CBFV – oxyHb++ 
Number of Subjects 15 16 10 10
Phase  (rad) -0.81 (0.29) -1.14 (0.67) -1.13 (0.44) -1.11 (0.57)
Gain (μmol/L/cm/s) 0.076 (0.021) 0.084 (0.05) 0.13 (0.049) 0.078 (0.02)
Coherence  0.53 (0.086) 0.60 (0.10) 0.60 (0.13) 0.57 (0.11)
Average of 5 and 4 minutes repeated sit-stand at 0.05 Hz and at 0.1 Hz, respectively. For CBFV either 
the average of left and right, or the available signal were included for analysis. Values are presented 
as mean, with standard deviation in parentheses. PS BP and PS CBFV denote spectral power of BP 
and CBFV.
Key: BP, blood pressure; bpm, beats per minute; CBFV, cerebral blood flow velocity; HHb, 
deoxygenated hemoglobin; HR, heart rate; nGain, normalized gain; oxyHb, oxygenated hemoglobin; 
PetCO2, pressure of end-tidal CO2; PS, power spectrum; TFA, transfer function analyses.
+ Data were only included if measurements on all signals were available.
++ Data were only included if coherence of the transfer function was >0.4.
* p < 0.01.
** p < 0.05.
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Figure 3   Example of the relation between BP and CBFV, and CBFV and oxygenated 
hemoglobin, during the repeated sit-stand maneuvers at 0.05 Hz 
Representative data from 1 healthy control is shown. The left panel presents the BP and CBFV 
changes (upper panel) and the CBFV and oxygenated hemoglobin (O2Hb; bottom panel) changes 
during the 0.05-Hz maneuver. The solid line represents changes in BP (upper panel), the long dashed 
line
represents changes in CBFV (upper and bottom panel) and the dotted line changes in O2Hb. Note 
that CBFV leads BP, whereas O2Hb lags behind CBFV. The data at 0.1 Hz are not shown because 
oscillations in O2Hb were not as clear as at 0.05 Hz.
133
CEREBRAL AUTOREGULATION IN ALZHEIMER'S DISEASE
6
Figure 4   Transfer function analysis of cerebral blood flow velocity and oxygenated 
hemoglobin in the frontal cortex in healthy controls and Alzheimer patients 
Values of transfer function analysis between cerebral blood flow velocity and oxygenated hemoglobin 
in healthy controls (CO) and Alzheimer patients (AD) in the very low (0.02– 0.07 Hz) and low (0.07– 
0.13 Hz) frequency range expressed in phase (upper panel), gain (middle panel), and coherence 
(bottom panel). Data of controls are presented left and of Alzheimer’s patients right. The box plots 
represents group average values with the 95% confidence interval. 




This study assessed dynamic cerebral autoregulation in patients with Alzheimer’s 
disease by means of the concomitant registration of changes in blood pressure, blood 
flow velocity in the middle cerebral artery, and cerebral frontal cortical oxygenation. 
There are three main findings in this study. First, in view of the fact that the origin of 
very low frequency oscillations in cortical oxygenation remains disputed, these data 
demonstrates that these oscillations are related to changes in global CBF, as measured 
in the middle cerebral artery, and that these CBF changes in turn were related to 
changes in systemic  blood pressure. Second, this study shows that by using repeated 
sit-stand maneuvers, the dynamic CBF-brain tissue oxygenation relation can be 
assessed using transfer function analysis during repeated sit-stand maneuvers 
associated with a high coherence function (> 0.4) between these variables. Third, we 
have shown that how changes in CBF are transmitted to changes in brain tissue 
oxygenation differs essentially between patients with Alzheimer’s disease and 
controls, as evidenced by increased transfer function gain and phase at 0.05 Hz 
between changes in CBF velocity and cortical O2Hb signal. 
Oscillations in Cerebral and Systemic Hemodynamics 
The NIRS method directly assesses cerebral cortical oxygenation changes at the 
cerebral cortical tissue level. In accordance with the literature, we detected 
spontaneous oscillations in O2Hb and HHb in the very low and low frequency 
range, where also spontaneous variability in BP and CBFV can be found.(6,20) 
Compared with healthy controls, AD patients had enhanced spontaneous 
oscillations in BP in the low frequency range (around 0.1 Hz), which led enhanced 
spontaneous oscillations in CBFV and O2Hb, but not HHb.  
 The repeated sit-stand maneuvers induced large oscillations in O2Hb that 
mirrored those in BP and CBFV. Thus far, only one study has succeeded in 
inducing oscillatory O2Hb changes, using deep breathing at 0.1 Hz, and these 
authors observed similar oscillations in BP, CBFV and O2Hb.(7) With a repeated 
sit-stand maneuver, we were able to induce oscillatory O2Hb changes in the very 
low frequency of 0.05 Hz, which would not have been possible with deep 
breathing. Our data indicate that oscillatory O2Hb changes in this frequency 
range are related to the oscillations in CBFV, which in turn are induced by 
oscillations in systemic BP. The larger oscillations in BP and CBFV at 0.05 
compared to 0.1 Hz during repeated sit-stand maneuvers are in agreement with 
previous studies.(9,10,21) Taken together, the relationship between BP, CBFV and 
O2Hb during repeated sit-stand maneuvers lends support to the notion that 
upstream oscillations in CBF induced by changes in BP contribute importantly 
to the downstream brain tissue level oscillations in O2Hb. 
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CBFV and Dynamic Autoregulation 
Confirming previous results from a pilot study measuring only CBFV, we 
observed that CBFV was reduced and cerebrovascular resistance was increased 
in AD.(4) This may be explained by enhanced vasoconstriction and other 
vascular factors such as a reduced cerebral capillary density and an aberrant 
vascular repair.(22) 
 We have previously shown that this difference could not be explained by 
differences in individual whole brain volume.(4) We could however, not 
reproduce the earlier findings of a lower gain between BP – CBFV during either 
the 0.05 Hz or 0.1 Hz repeated maneuver in AD relative to controls. An important 
difference between these studies is that in the present study, patients were not 
treated yet with cholinesterase inhibitors. These drugs potentially alter cerebral 
hemodynamics.(23)  Moreover, AD patients in the present study were older.   
 The CBF response to transient changes in BP, as quantified by transfer 
function gain and phase, reflects dynamic cerebral autoregulation.(11)  The 
mechanisms underlying dynamic autoregulation are not clear. The unaltered 
gain and phase between BP and CBFV observed in this study suggest that 
dynamic autoregulation –at least at the macrovascular level- is preserved in 
patients with AD. However, dynamic cerebral autoregulation was impaired in 
the mouse models of AD related to beta amyloid pathology.(2,3) These 
discrepancies may highlight the differences in the regulation of cerebral 
hemodynamics between patients with AD and the animal model used. Clearly, 
further work is needed to understand the regulation of CBF and its relation to 
AD pathology.   
The Dynamic CBFV- O2Hb Relationship
The dynamic relation between oscillations in CBFV and cortical O2Hb may 
reflect a regulatory mechanism to maintain brain tissue oxygenation homeostasis.
(3,17) However, the investigation of the relationship between spontaneous 
oscillations in CBFV and O2Hb using transfer function analysis suffers from the 
weakness and non-stationarity of the O2Hb measurement under resting 
conditions.(17) The repeated sit-stand maneuvers in this study induced large 
oscillations in BP, CBFV, and O2Hb and enhanced coherence  between CBFV – 
O2Hb (> 0.4) and therefore improve the reliability of the transfer function 
analysis.(5)
 CBFV was measured in the MCA. NIRS measurement was obtained from 
the medial-frontal cortex areas which are dependent for their blood supply on 
the anterior cerebral artery (ACA) as well as the MCA. We assumed that relative 
change of CBFV in the MCA would be the same for the relative change of CBFV 
in the ACA in response to a change in blood pressure. 
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 O2Hb oscillations seem to follow those of CBFV (Figure 3). Therefore, the phase 
difference between these variables may reflect a transit time between flow in 
supplying brain arteries and O2Hb. In patients with AD, a disease in which it 
becomes progressively clear that the cerebral microvasculature is affected, we 
identified a larger phase lag and higher gain between CBFV and O2Hb at the 
very low frequency of 0.05 Hz –where dynamic cerebral autoregulation is active- 
but not in the low frequency (0.1 Hz) –where autoregulation is less active.(24) 
Because O2Hb is a correlate of local blood flow, this might point to a differential 
transfer of central blood flow to local blood flow and to local cerebral oxygenation 
in Alzheimer’s disease. Whether this is due to differences in active regulation 
mechanisms or due to differences in the passive properties of the cerebral 
vasculature is not clear.(25)  The increases in the transfer function gain between 
CBFV and O2Hb provide further insights into the cerebral microvascular 
function in AD. Using positron emission tomography (PET), it has been shown 
that the oxygen extraction fraction, regarded as an indicator of the brain tissue 
metabolic reserve, was increased in AD  (a reduction of metabolic reserve).(8) In 
addition, reduced brain metabolic rate for glucose and oxygen has been observed 
in AD which may reduce the oxygen diffusion gradient from the capillaries to 
brain tissue. Therefore, the increase in CBFV - O2Hb gain might also reflect a 
reduced metabolic reserve or a reduced diffusion of oxygen leading to enhanced 
oscillations in [O2Hb] in response to changes in CBF.   
 The specific mechanisms for the altered CBFV – O2Hb relationship in AD 
cannot be determined in this study. Amyloid beta, the peptide linked to the 
pathological manifestations in AD, causes cerebrovascular dysfunction 2 as well 
as deposits in the small vessels in AD (cerebral amyloid angiopathy). In turn, the 
brain microcirculation not only responds to amyloid beta, but also regulates 
amyloid beta.(26)  It is possible that these abnormalities may contribute to the 
altered CBFV- O2Hb relation. Further, the enhanced oscillations of O2Hb in 
response to changes in CBF  may lead to local hypoxic changes in the brain that 
in turn could establish a vicious circle: over expression of transcription factors 
in smooth muscle cells of small brain arteries promote a hypercontractile 
phenotype of cerebral arteries, which may increase the CVR, and in turn leads 
to hypoxia.(27)
Study Limitations
Significantly more  patients however used antihypertensive drugs. However, 
cerebral autoregulation and cerebral blood flow are preserved during treatment 
with β-blockers, calcium channel blockers, angiotensin-converting enzyme 
inhibitors, AT1-recepter blockers, or thiazide diuretics.(28-32)
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 In the AD group, 5 subjects suffered from type 2 diabetes mellitus. Data 
regarding the influence of diabetes mellitus on cerebral autoregulation are 
mixed, reporting either an impairment or preservation of cerebral autoregulation.
(33-35) For the analysis of the relation between CBFV – O2Hb at 0.05 Hz -where 
the current study demonstrated an altered relationship in AD-, only 2 diabetic 
AD patients were included. This makes a confounding effect of diabetes on our 
findings very unlikely. 
 Moreover, hypertension and diabetes mellitus are the most important 
vascular risk factors for AD(36), and exclusion of AD patients with such 
comorbidities from studies would seriously hamper their generalizability . 
 Both methods to assess cerebral perfusion, TCD and NIRS, have certain 
limitations that have been well described in the literature and that are 
summarized in the Methods section. We combined these two measurements to 
provide information on both global cerebral perfusion and brain tissue level 
oxygenation in patients with AD. 
Conclusion
Using a unique combination of Finapres, TCD, and NIRS measurements, we 
have shown that oscillations in cerebral blood flow velocity, induced by repeated 
changes in body posture, translated into large oscillations in cerebral cortical 
oxygenation. Furthermore, the dynamic relation between cerebral blood flow 
velocity and cerebral cortical oxygenation can be assessed using transfer 
function analysis during repeated sit-stand maneuvers. Finally, we demonstrated 
that Alzheimer patients differed from controls in how these changes in flow 
were transmitted to changes in cerebral cortical oxygenation.  This result might 
be  indicative of either altered properties of the cerebral microvasculature or 
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This thesis started with Mrs. X. Her case gave rise to the following questions. In 
short, do orthostatic hypotension (OH), postprandial hypotension (PPH), and 
carotid sinus hypersensitivity (CSH) share a common pathophysiology and do 
they predict mortality? Does the blood pressure (BP) decrease directly after 
standing, but also the degree of BP recovery afterwards, predict mortality? 
Does Alzheimer’s dementia (AD) affect BP regulation through the baroreflex 
sensitivity (BRS) and does cholinesterase inhibitor use influences this BRS? And 
finally, does AD impair dynamic cerebral autoregulation? The answers are given 
in the summary below.  
 OH, PPH and CSH are disorders of  BP regulation with high prevalence in 
the elderly. The exact pathophysiology of these hypotensive syndromes is not 
clear and rarely studied together. The cardiovascular autonomic system plays an 
important role in the short-term regulation of BP. In Chapter 2a we compared 
14 different non-invasive autonomic function indices of heart rate variability 
(HRV), BP variability (BPV), and BRS in a cohort of 203 patients visiting our falls 
and syncope outpatient clinic. We found no differences of these measures in 
geriatric patients with hypotensive syndromes compared to geriatric patients 
without these hypotensive syndromes. Patients with and without falls, dizziness, 
or syncope as presenting symptom did not show differences in these indices 
either. These findings argue against a single or dominant etiological factor, i.e. 
autonomic dysfunction, in the etiology and pathophysiology of these hypotensive 
syndromes. It also underscores the need for a multifactorial approach in 
diagnostic investigations of elderly with falls and/or syncope.
 In Chapter 3a we applied an  alternative approach to study whether there is 
indirect evidence for a shared similar pathophysiology in OH, PPH and CSH. 
Therefore we examined the occurrence of these three syndromes in a cohort of 
313 patients visiting our falls and syncope outpatient clinic (this cohort includes 
the 203 patients of chapter 2). We studied the co-occurrence of OH, PPH, and 
CSH in the same patient and determined, if it occurred more often than chance. 
Although OH, PPH, and CSH had a high prevalence of 54%, 58%, and 53%, 
respectively, and occurred frequently together in the same patient, there was no 
clustering of these syndromes. This absence of clustering of hypotensive 
syndromes in the same patients suggested different underlying pathophysiological 
mechanisms for the different hypotensive syndromes. Besides clustering, we 
also studied the impact of the three hypotensive syndromes on all-cause 
mortality. During a median follow-up of 23.0 months, 58 (19%) patients died. We 
found that OH, but not PPH or CSH, predicted mortality (hazard ratio: 1.97; 95% 
confidence interval: 1.11-3.47). This relationship was no longer significant after 
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adjusting for age, comorbidity and other baseline characteristics. However, OH 
with a severe DBP decrease of 20 mmHg or more remained a powerful 
independent predictor of mortality (hazard ratio: 2.50; 95% confidence interval: 
1.20-5.22), and therefore might be used prognostically as an easily available 
cardiovascular sign of increased mortality risk.
 While the previous chapter looked at the influence of BP decline between 1 
and 3 minutes after standing (OH) and mortality, Chapter 4 investigated the 
association of mortality with BP decrease and recovery in the first minute 
directly after standing. This was done in a cohort of 238 patients visiting our 
falls and syncope outpatient clinic as part of the larger cohort of 313 patients 
described in chapter 3. During a median follow-up of 21.0 months, 36 (15%) 
patients died. Systolic BP (SBP) and DBP decreased maximally with 42 ± 25 
mmHg and 23 ± 15 mmHg, respectively, from baseline within the first 15 seconds 
directly after standing, corresponding with 75 ± 15% and 71 ± 16% of the baseline 
SBP and DBP. Neither the absolute nor the relative initial BP drop after standing 
predicted mortality. However, the percentage of BP recovery 40 to 60 seconds 
after standing was associated with mortality, even after adjustment for age, 
comorbidity and other baseline characteristics. SBP recovery of less than 80% 
from baseline after 60 seconds was a powerful independent predictor of 
mortality (hazard ratio: 3.00; 95% confidence interval: 1.17-7.68).
 AD is a frequent occurring progressive neurodegenerative disorder which 
places a huge burden on society and individual caregivers. Cardiovascular factors 
are commonly accepted as risk factors for AD, however, the exact relationship 
between these factors and AD remains poorly understood. The cholinergic 
system is an important component of cardiovascular and autonomic control, 
including the baroreflex and this cholinergic system is known to be affected in 
AD. Therefore, in Chapter 5a we studied the baroreflex in 18 AD patients, 11 
patients with mild cognitive impairment and 19 age and sex matched healthy 
controls. The baroreflex was reduced in AD compared to patients with mild 
cognitive impairment and the healthy controls. This result was reproduced in an 
independent validation sample of 16 AD patients, 18 patients with mild cognitive 
impairment and 19 age and sex matched healthy controls. Treatment of 18 AD 
patients with acetylcholinesterase inhibitor increased baroreflex sensitivity 
with 66%. In summary, the baroreflex is reduced in AD and increases after 
treatment with acetylcholinesterase inhibitor. The pathophysiological and 
diagnostic value of this association between impaired baroreflex and AD needs 
further research.  
 Finally in Chapter 6, the association of AD with dynamic cerebral auto-
regulation and brain tissue oxygenation was studied. In 21 patients with mild to 




cerebral blood flow velocity (CBFV) and O2Hb are associated with oscillations in 
BP induced through repeated sit-stand maneuvers at 0.05 Hz and 0.1 Hz. In AD, 
cerebrovascular resistance was 34% higher, compared to the age matched 
controls. Despite a higher cerebrovascular resistance, there was no difference in 
dynamic autoregulation between patients with AD and healthy control. 
However, in patients with AD, the translation of CBFV to O2Hb essentially 
differed from age matched healthy controls. In AD, these results of an elevated 
cerebrovascular resistance and an altered transfer of cerebral blood flow to 
cortical oxygenation, might indicate altered properties of the cerebral micro-
vasculature or altered brain tissue oxidative metabolism. 
General discussion
The studies conducted in this thesis are part of an active, ongoing scientific 
debate on the causes of syncope and falls on the one hand, and the age related 
changes in pathophysiology and prognosis of blood pressure and cerebral 
perfusion regulation disturbances on the other. We strongly felt that participation 
in this scientific debate stimulated our own scientific work and was an essential 
part of it, and therefore wrote several letters to the editor and to our research 
colleagues, which are also part of this thesis. Together they give an impression 
of hypotheses tested by fellow researchers, and show that our work fits well in 
the highly relevant and urgent quest for better understanding of the specific 
age-related changes in homeostasis of hemodynamics in our aging societies.
 In Chapter 2b we positioned our work in the debate on the relevance of the 
mono-causal oriented adenosine 5’-triphosphate testing in a heterogenic 
geriatric falls population with multicausal etiology.(1,2) Our letter highlights 
methodological issues of the representativeness of the studied research 
population. This issue of external validity or generalizability of the presented 
research results of this thesis, always a key-question in valueing aging and 
geriatric research studies, will be put into perspective and discussed further in 
the section Methodological considerations below.
 In Chapter 3b we argue in another letter  that besides  visit-to-visit BPV, the 
postural or postprandial change of BP might also contain additional prognostic 
information.(3,4) In Chapter 3c we questioned the prognostic meaning of the 
change of postural DBP in middle aged adults on mortality.(5,6) In Chapter 5b 
the potential additive prognostic information of BPV above and beyond mean 
BP is suggested for white matter hyperintensities and cognitive decline in older 
people.(7,8) These three chapters have prognostication in common and the 
prognostic information of the presented research results of this thesis will be 
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discussed in a broader context in the section Clinical (and research) implications 
below. 
Methodological considerations
This thesis investigated a selective patient population of 313 patients who were 
referred to an out-patient geriatric falls and syncope clinic, because of syncope, 
falls and/or dizziness. This has the disadvantage of a specific selection and 
therefore our sample is not a representative for the general population, but only 
for populations referred to similar outpatient clinics. Between 30 % and 40 % of 
community dwelling adults aged 65 years or older fall at least once per year.(9) 
Only a fraction of these older adults visits a general practitioner or emergency 
department and of those also only a fraction is referred to a fall clinic. The source 
of referral to a fall clinic (general practitioner or emergency department), has 
substantial influence on the case-mix.(10) This highly selective nature of falls 
and syncope patients referred to the fall clinic, in contrast to the general elderly 
population is highlighted in Figure 1. 
Figure 1  Venn diagram of elderly (falling) population 
GP, general practitioner; ED; emergency department.
General elderly population 
General elderly falling population 
 
Falling elderly 








The 313 patients we studied represent a very heterogeneous study group. 
Importantly, they were all patients referred (merely all by the general practitioner) 
to our academic falls and syncope outpatient clinic. Next, patients were only 
excluded if they were not able to follow the instructions, could stand for 10 
minutes and could drink a test meal of 200 ml within 10 minutes. Patients were 
not excluded because of certain diseases (for example heart failure, diabetes 
mellitus, Parkinson’s disease or dementia), organ dysfunctions (for example 
renal failure) or age. Although heterogeneous, this prevented underrepresentation 
of certain patient characteristics in the research population as has been observed 
in the representation of elderly in cardiovascular, oncologic or pharmaceutical 
clinical trials.(11-14) Of the 313 patients, two rather large groups were excluded 
in the two studies investigating mortality. First, in Chapter 3a, carotid sinus 
massage (CSM) was not performed in 41 (13%) patients because they met the 
exclusion criteria. Accepted contraindications were taken as exclusion criteria 
for CSM: a murmur over the carotid artery, myocardial infarction, cerebral 
ischemia in the past 3 months, or a history of ventricular tachyarrhythmia’s.(15). 
Second, in Chapter 4, 71 patients were excluded because there were no raw data 











Age 78.0±8.1 83.1±6.3* 78.4±7.9 79.7±8.5
BMI 26.5±4.4 26.0±4.0 26.5±4.6 26.0±3.9
Female, n(%) 61% 73% 64% 59%
Baseline SBP 168±25 175±33 168±26 173±27
Baseline DBP 78±12 79±12 79±12 79±13
Baseline heart rate 67±11 74±13* 68±12 68±12
CIRS-G total score 11.2±4.6 12.5±4.4 11.1±4.5 12.3±4.9†
Hazard ratio 1 2.97 (1.71-5.14) 1 1.43 (0.82-2.50)
Hazard ratio, adjusted 1 1.72 (0.91-3.26) 1 0.98 (0.54-1.78)
Results are reported as means ± standard deviations or numbers (percentages). Age(years); BMI, 
body mass index(kg/m2); BP, blood pressure(mmHg); heart rate(beats per minute); CIRS-G, 
Cumulative Illness Rating Scale for Geriatrics. *:significant differences (p<0.05) between patients 
with and without CSM; †:significant differences (p<0.05) between patients with and without the 
availability of the raw data files.
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The table above compares the baseline variables of patients with and without 
CSM and the with or without the availability of the raw data files. Patients who 
were excluded for CSM were older and had a higher baseline heart rate. There 
was also a tendency to higher comorbidity burden, higher SBP and more female 
sex, but these differences were not significant. The patients of whom the raw 
data were stolen had higher comorbidity burden and a tendency to be older en a 
higher SBP but these differences were not significant. The unadjusted hazard 
ratio for mortality among the “stolen” patient population had a tendency to be 
higher than the subpopulation with availability of the raw data, however this 
was also not statistically significant. After adjusting for baseline variables the 
hazard ratio decreased to unity. Although this stolen data were assumed to be a 
random selection, the populations differed on some aspects of baseline variables. 
Nevertheless, after correction for these differences there was no difference in 
mortality, which supports the assumption that it was a random selection, free 
from selection bias or bias by indication. On the other hand, the population in 
which no CSM was performed also differed in baseline characteristics with 
respect to the subpopulation of patients in which CSM was performed. Here the 
unadjusted hazard ratio for the subpopulation without CSM was much higher 
than the subpopulation of patient where CSM was performed. Even after 
correction for baseline variables this tendency remained, but was no longer 
statistical significant. This might point at residual confounding by indication; 
the population which was excluded for CSM was not only different at baseline, 
but might also be at higher risk of mortality by other factors than the baseline 
variables. Unfortunately, this reasoning cannot be completely evidenced 
because the tendency to a higher hazard ratio after correcting is not statistically 
significant. This might be due to the relative small studied population and for 
this comparison the study probably is  underpowered. Because of the patho-
physiology and prognosis related mechanisms of the selection, it is likely that in 
the CSM case, absence of evidence is not the same as evidence of absence. 
 To illustrate the possibility that the sample size is relatively small to extract 
all information, we extended some analyses of Chapter 3a. In this study, the 
association of the amount of SBP and DBP decrease during testing for OH on 
mortality was investigated. Therefore SBP and DBP decline subgroups were 
defined as a decline of < 20 (no OH), 20 to 35, and ≥ 35 mmHg for SBP and a 
decline of < 10 (no OH), 10 to 20, and ≥ 20 mmHg for DBP, respectively. We 
showed that DBP decline of ≥ 20 mmHg was independently associated with 
mortality, whilst SBP decline was not associated with mortality. We repeated the 
same analysis for SBP and DBP as a continuous variable. After correction for the 




1.09 (1.01-1.17) and 1.25 (1.06-1.49), respectively. This indicates that SBP decrease 
is associated with increase in mortality, although to a much smaller degree than 
DBP decrease. Besides the relative small sample size, this example also illustrates 
the loss of information by using categorized variables compared to continuous 
variables in this analysis. 
 Another consequence of a relative small sample size is the limiting amount 
of covariates which can be used. In Chapter 3a there were 58 events and we used 
the covariates age, gender, BMI, comorbidity (CIRS-G score), medication use and 
baseline SBP and DBP. Medication use consisted of 9 medication groups, so in 
total 15 covariates were used, i.e. approximately 4 events per covariate. When 
excluding medication use, or replacing it for polypharmacy (using 4 or more 
medications), the total covariates used changed to 6 or 7, i.e. approximately 8-9 
events per covariate. This did not change the main results. In Chapter 4 there 
were 36 events and we used 7 covariates, i.e. approximately 5 events per 
covariate. Although as a rule of thumb often approximately 10 events per 
covariate is claimed to be necessary, there is evidence that this can be lowered to 
5-9 or even less events per covariate, without losing accuracy and validity in the 
control of confounding.(16) As a consequence of our sample size, we arrived at 
the limit of covariate correction in our analyses, which is often the case in 
studying older populations with comorbidity and high levels of hetereogeneity.
 The 313 patients in our study represent a rather frail and vulnerable geriatric 
population group with a mean age of 79 ± 8 year and a CIRS-G comorbidity 
score of 11.4 ± 4.6. In comparison, a population of 252 patients ≥ 75 year on a 
general geriatric rehabilitation unit had approximately the same CIRS-G 
comorbidity score, but had a substantially higher mean age of 85 years.(17) In 
contrast, a population of 102 hip fracture patients aged ≥ 65 year admitted on a 
geriatric rehabilitation unit and a population of 212 patients aged ≥ 65 year 
admitted on a acute geriatric ward were of approximately the same mean age of 
79 and 81 year, respectively, but had a substantially lower CIRS-G comorbidity 
score of 9.9 and 9.2 respectively.(18,19) 
 In summary, the external validity from our findings to the general elderly 
population is limited. However, the geriatric population visiting the falls and 
syncope clinic is the population with the highest relevance of hypotensive 
syndromes and therefore our research results are applicable to those patients 
with the restriction that they have approximately the same baseline characteris-
tics (i.e. age and comorbidity). In sum, our results probably hold true for the 
most frail older subjects with falls and related blood pressure regulation 
disturbances, which is an understudied  population so far.
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Clinical (and research) implications: prognostics 
As mentioned above in the general discussion, one of the main potential 
implications of the presented research in this thesis lies in prediction. Prediction 
of mortality on the one hand and prediction of Alzheimer dementia on the other. 
Some additionally remarks will be made on the subject of prediction and 
prognostics below. 
 The following characterization, made in 1934, of prognosis remains still 
accurate today: “Of the three great branches of clinical science -diagnosis, 
prognosis, and treatment- prognosis is admittedly the most difficult. It is also 
that about which least has been written and of which our knowledge is least 
systematized.”(20)  This undervaluing of prognostic research lasts until now. 
Just very recently Hemingway et al.(21) argued for the recognition of the 
importance of this scientific domain and  strongly plead for improved methodology. 
Of the four forms of prognostic research themes, two were addressed in the 
papers presented in this thesis: 
- Specific factors (such as biomarkers and BP changes after standing) that are 
associated with prognosis (prognostic factor research) 
- The development, validation, and impact of statistical models that predict 
individual risk of a future outcome (prognostic model research, eg the 
regression models found in our studies)
Despite the difficulty of adequate prognostic validation studies, which are often 
time consuming and thus expensive, they are increasingly important, especially 
in geriatric patients who encounter a shrinking horizon of their life expectancy.
(22) Guidelines increasingly incorporate life expectancy as a central factor in 
weighing the benefits and the burdens of tests and treatments.(23) However, 
geriatric assessment is time-consuming and other medical specialists are not 
trained for this kind of assessment, therefore geriatric assessment has not 
typically been used in daily practice to assist in decision making. Therefore, 
there is increasing interest in finding predictors that are easy applicable, 
non-invasive, time efficient, cost-effective and have low patient burden as in 
clinical practice simpler models are more practical.(24) Studenski et al. 
impressively showed that gait speed, additive to age and sex, was as accurate in 
predicting survival in older adults as age, sex, walking aid use and variables of 
functional status, especially after age 75 years.(25) Similarly, in predicting 
morbidity and mortality following cardiac surgery, gait speed was at least as 
strong as a predictor as far less efficient traditional cardiac measures (eg. ejection 
fraction and composite cardiac risk scores).(26) In aging, BP does not tell it all 
and becomes a “poor story teller”, hence the need for alternative simple, 
non-invasive risk factors like for example pulse wave analysis or velocity(27) or 




informative predictors, BP decline after standing might be a candidate predictor 
because it has additional prognostic information above age, sex, comorbidity 
and BP. 
 Syncope can be classified in three groups: reflex or neurally-mediated 
syncope, syncope due to OH and cardiac syncope.(29) Patients with reflex 
syncope have a normal prognosis, whilst patients with a cardiac syncope have a 
higher mortality risk.(30) Also middle aged patients with syncope due to OH 
have a higher mortality risk.(31) Our results are in line with these observations, 
as PPH and CSH are classified as neurally-mediated syncope(29) and not 
associated with mortality, whilst OH is in elderly patients still associated with 
an increased mortality. After correcting for baseline variables this association is 
no longer statistical significant. However, the amount of SBP and DBP drop 
during OH measurement remains significantly associated with mortality as is 
the case for SBP and DBP in middle-aged persons.(5,6) From our results no 
conclusions can be drawn about causality. Cause specific mortality might help, 
but is not conclusive. Mortality through injuries is likely, but not necessarily, 
caused by OH. Moreover, the association between OH and cardiovascular 
disease can be both cause and effect. Thus, a dual role of orthostatic hypotension 
in prediction of adverse events, both as the causal factor and as an independent 
marker of underlying diseases is most likely.(32) Our result of the association of 
impaired BP recovery directly after standing and mortality, shows that BP 
regulatory systems are affected and that this dysregulation predicts mortality. 
Our results are in line with findings in 374 patients aged 70.2 ± 8.5 years of one 
primary care practice, in which inappropriate recovery was prognostically more 
important than the immediate blood pressure fall itself after standing.(33) 
 As mentioned above, we compared in Chapter 2a 14 different non-invasive 
autonomic function indices of HRV, BPV and BRS and we found no differences 
of these measures in geriatric patients with hypotensive syndromes compared 
to geriatric patients without these hypotensive syndromes. Although we studied 
the association between mortality and hypotensive syndromes, we did not 
study the association of these indices with mortality. The clinical relevance of 
diminished HRV preceding fetal death was first recognized in 1963.(34) HRV 
and BRS have significant prognostic value, independently of left ventricular 
ejection fraction, in patients with a recent myocardial infarction.(35) Also in an 
elderly population of 72 ± 6 years, HRV measures offers prognostic information 
independent of and beyond that provided by traditional risk factors.(36) However, 
in a general population, blood pressure variability did not incrementally predict 
outcome over and beyond mean systolic blood pressure.(37) We studied the 
association of these indices with mortality. All 5 HRV indices, none of the 4 BPV 
indices and 2 (SD-BRS and SQ-BRS-) of the 5 BRS indices were significantly 
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associated with mortality (for explanation of these indices see Chapter 2a). After 
correction for age, sex, BMI, comorbidity and baseline SBP, DBP and heart rate 
this association remained significant for 3 (RMSSD-HRV, LF-HRV and HF-HRV) 
of the 5 HRV indices and SQ-BRS- as BRS index. This remained the same even 
after further adjustment of the DBP decrease during OH testing (Chapter 3a) 
and/or percentage SBP recovery 55-60 seconds after standing (Chapter 4).
 In conclusion, besides certain BP indices after standing up, also certain HRV 
indices measured during rest, can be used as easy applicable, non-invasive 
prognostic factors which contain additional prognostic information above age, 
sex and comorbidity.    
 Another form of prognosis or prediction, is the diagnostic prediction of AD. 
How should BRS as potential biomarker of AD be interpreted and implemented? 
We validated the discriminatory role of BRS for AD using an independent data 
set. In Chapter 2 we determined HRV, BPV but also BRS indices in a elderly falls 
population. Of this population 6% was diagnosed with any form of dementia. 
We found no differences in HRV, BPV or BRS indices between falls patients with 
and without dementia. This is possibly due to the small sample of falls patients 
with dementia, the mixed etiology of dementias and because another method 
was used to determine BRS than in Chapter 5a. For a clinically meaningful 
interpretation, the BRS should not be interpreted on its own, but should be 
instead weighed against the previous probability of AD, which the clinician 
derives from interpretation of a combination of history taking, physical 
examination, neuropsychological evaluation, and neuroimaging.(38) A common 
limitation in dementia research for the use of BRS is that the clinical diagnosis is 
used as a reference standard. Because the clinical diagnosis is the reference 
standard, it is difficult to assess the potential influence of BRS on this clinical 
diagnosis, as it is not yet part of this clinical diagnosis. More prospective 
research is necessary to answer this question and to determine the potential role 
for BRS in the diagnosis of AD. 
Future perspectives
Life is a highly organized complex state of an organism, operating in an 
equilibrium that is far from stable, yet sufficiently robust to resists the permanent 
attacks from its environment. During aging the capability to resist these 
environmental attacks diminishes and the system often enters a state of 
increased vulnerability to poor resolution of homeostasis after a stressor event, 
also defined as frailty.(39) As populations are quickly aging, the prediction of 




functional performance are of crucial importance for medical decision making 
both at the level of the individual patients and the society. 
 The human body has the structure of a network of coupled dynamical 
systems. Organs such as the heart, lungs and brain are highly clustered networks 
that are interconnected with each other by a few long range edges like the humoral 
system and autonomic neuronal system. The structure of for instance the 
His-Purkinje neural network(40) and the bronchial tree(41) is that of a scale free 
power law network.(42,43) Besides the complex structure, the function of different 
organs also exhibit complex dynamics like for example the regulation of heart 
rate(44-46), respiration(47), gait(48,49) and temperature.(50) Loss of this complex 
dynamic behavior can predict sudden cardiac death(51) and is associated with a 
breakdown in cognition.(52) Thus, network-theoretical properties appear useful 
as biomarkers of physiologic aging and therefore are likely to be valid measures of 
frailty.(53,54) Frailty is a state of critical loss of physiological complexity that 
results in heightened vulnerability to stressors.(54)  Frailty and aging are 
characterized by the accumulation of deficits over time. Deficits can be defined as 
abnormalities of body areas and human behaviour and can include variables on 
physical function, psychological function, cognitive function, comorbidity, and 
health attitudes.(55,56) There is evidence for a limit in the maximum of deficit 
accumulation.(57) When this limit is crossed it seems not reconcilable with life in 
the long run, but patients may stay a longer period on this edge of frailty instability. 
Further loss results in a breakdown of the system with abrupt transitions like 
geriatric syndromes as falling, delirium or even a cascade of malfunctioning 
organs, and ultimately death. Therefore, frailty, being a state of critical loss of 
complexity, is increasingly studied by nonlinear models.(58-60) Slowing down of 
recovery time is an early warning signal of approaching abrupt critical  transitions 
(tipping points) in complex systems.(61-66) From the emerging field of complex 
system biology, there is firm experience and evidence for critical slowing down as 
an early warning signal in physics, chemistry, climate changes and ecology(62,67-
71), however the use and evidence in medicine is sparse. In medicine, critical 
slowing down of recovery may be used to rank complex organ systems on a broad 
scale from resilient to fragile, and may be used as early warning signals for 
closeness to a tipping point both in normal physiology and in chronic disease. The 
results of Chapter 4 can be seen as an example of slowing down of SBP recovery, 
and hence loss of complexity and higher mortality. For clinical practice, the simple 
maneuver of standing up is an excellent stress test and perturbation of the neuro-
cardiovascular system with good prognostic value depending on the amount and 
speed of SBP recovery.   
 Because of the complex nature of aging processes, present reductionistic 
methods are not adequate for defining good health or healthy aging. Due to its 
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capacity to characterize complex dynamics within and between physiological 
systems, the emerging field of complex systems biology and its array of 
quantitative tools, such as the aforementioned critical slowing down, show great 
promise for improving our understanding of aging, monitoring senescence, and 
providing biomarkers for evaluating novel interventions that treat age-related 
disease and promote healthy aging.(72-74) Future research should focus on the 
determination of early signs of imminent transition states, so called frailty 
states, of the complex system of organ function interactions. Hereby, not only 
prognosis, but also prevention of complications by early detection of frailty 
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Samenvatting
Dit proefschrift gaat over bloeddruk regulatie en cerebrale autoregulatie bij 
enerzijds oudere patiënten die een val-en-syncope-polikliniek bezochten en 
anderzijds patiënten met een Alzheimer dementie (AD). Dit proefschrift 
behandelt de volgende vragen: 1) delen orthostatische hypotensie (OH), 
postprandiale hypotensie (PPH) en carotis sinus overgevoeligheid (CSH) een ge-
meenschappelijke pathofysiologie en voorspellen ze mortaliteit? 2) Voorspellen 
de bloeddruk daling direct na opstaan, en de mate van bloeddruk herstel, 
mortaliteit? 3) Is AD van invloed op de baroreflex gevoeligheid (BRS) en 
beïnvloedt cholinesteraseremmer gebruik deze BRS? 4) En ten slotte, tast AD de 
dynamische cerebrale autoregulatie aan? 
OH, PPH en CSH zijn aandoeningen van de bloeddruk regulatie met een hoge 
prevalentie bij ouderen. De exacte pathofysiologie van deze hypotensieve 
syndromen is niet duidelijk en zelden samen bestudeerd. Het cardiovasculaire 
autonome systeem speelt een belangrijke rol in de korte termijn regulatie van de 
bloeddruk. In hoofdstuk 2a vergeleken we 14 verschillende niet-invasieve 
autonome indices van de hartslag variabiliteit (HRV), bloeddruk variabiliteit 
(BPV) en BRS in een cohort van 203 patiënten die onze val-en-syncope-polikli-
niek bezochten. We vonden geen verschillen in deze indices tussen geriatrische 
patiënten met een van deze hypotensieve syndromen in vergelijking met 
geriatrische patiënten zonder een van deze hypotensieve syndromen. Er was 
ook geen verschil in deze indices tussen patiënten met en zonder valpartijen, 
duizeligheid of syncope. Deze resultaten pleiten tegen autonome dysfunctie als 
enige of dominante factor in de etiologie en pathofysiologie van deze 
hypotensieve syndromen. Het onderstreept ook de noodzaak van een multifac-
toriële aanpak in diagnostische onderzoeken van ouderen met vallen en/of 
syncope.
 In hoofdstuk 3a onderzochten we of er indirect bewijs is voor een gedeelde 
pathofysiologie in OH, PPH en CSH. Hiertoe hebben we gekeken naar de 
aanwezigheid van deze drie syndromen in een cohort van 313 patiënten die 
onze val-en-syncope-polikliniek bezochten (dit cohort omvat ook de 203 
patiënten van hoofdstuk 2). We bestudeerden het co-optreden van OH, PPH en 
CSH in dezelfde patiënt en bepaalden of dat vaker optrad dan het toeval. Hoewel 
OH, PPH en CSH een hoge prevalentie hadden van respectievelijk 54%, 58% en 
53%, en dus vaak samen voorkwamen in dezelfde patiënt, was er geen sprake 
van clustering van deze syndromen. Deze afwezigheid van clustering suggereert 
verschillende onderliggende pathofysiologische mechanismen voor deze drie 
verschillende hypotensieve syndromen. Naast clustering, onderzochten we ook 
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de impact van deze hypotensieve syndromen op mortaliteit. Gedurende een 
mediane follow-up van 23 maanden overleden 58 (19%) patiënten. OH, maar niet 
PPH of CSH voorspelde mortaliteit (hazard ratio: 1,97; 95% betrouwbaarheidsin-
terval: 1,11 - 3.47). Deze relatie was niet meer significant na correctie voor leeftijd, 
comorbiditeit en andere baseline kenmerken. Echter, OH met een diastolische 
bloeddruk daling van 20 mmHg of meer bleef, ook na correctie, een krachtige 
onafhankelijke voorspeller van mortaliteit (hazard ratio: 2,50; 95% betrouwbaar-
heidsinterval: 1.20 -5.22), en kan daarom prognostisch gebruikt worden als 
een gemakkelijk beschikbaar cardiovasculaire maat van een toegenomen 
sterfterisico.
 Terwijl in het vorige hoofdstuk werd gekeken naar de invloed van de 
bloeddruk daling tussen 1 en 3 minuten na opstaan  (OH) op mortaliteit, 
onderzochten we in hoofdstuk 4 de associatie van sterfte met de bloeddruk 
daling en ook het herstel in de eerste minuut na opstaan. Dit werd gedaan in een 
cohort van 238 patiënten die onze val-en-syncope-polikliniek bezochten als 
onderdeel van het grotere cohort van 313 patiënten beschreven in hoofdstuk 3. 
Gedurende een mediane follow-up van 21 maanden overleden 36 (15%) patiënten. 
De systolische en diastolische bloeddruk daalden gemiddeld maximaal met 42 
± 25 mmHg en 23 ± 15 mmHg binnen de eerste 15 seconden na opstaan, hetgeen 
overeenkomt met 75 ± 15% en 71 ± 16% van de baseline systolische en diastolische 
bloeddruk. Noch de absolute, noch de relatieve bloeddruk daling direct na 
opstaan  voorspelden mortaliteit. Echter, het percentage herstel van de bloeddruk 
40 tot 60 seconden na opstaan is wel geassocieerd met oversterfte, zelfs na 
correctie voor leeftijd, comorbiditeit en andere baseline karakteristieken. Een 
systolisch bloeddruk herstel van minder dan 80% van de uitgangswaarde na 60 
seconden was een krachtige onafhankelijke voorspeller voor mortaliteit (hazard 
ratio: 3,00; 95% betrouwbaarheidsinterval: 1,17 - 7,68).
 AD is een veel voorkomende progressieve neurodegeneratieve aandoening 
die een zware last legt op de samenleving en individuele zorgverleners. Cardio-
vasculaire factoren worden algemeen aanvaard als risicofactoren voor AD, maar 
de precieze relatie tussen deze factoren en AD blijft onduidelijk. Het cholinerge 
systeem (waaronder de baroreflex) is een belangrijk onderdeel van de cardiovas-
culaire en autonome regulatie, en AD tast dit cholinerge systeem mogelijk aan. 
Daarom is in hoofdstuk 5a de baroreflex bestudeerd in 18 AD patiënten, in 11 
patiënten met milde cognitieve stoornissen en in 19 leeftijd en geslacht gematchte 
gezonde controles. De baroreflex is verminderd in AD in vergelijking met 
patiënten met milde cognitieve stoornissen en de gezonde controles. Dit resultaat 
werd gereproduceerd in een onafhankelijke validatie steekproef van 16 AD 
patiënten, 18 patiënten met milde cognitieve stoornissen en 19 leeftijd en geslacht 
gematchte gezonde controles. De behandeling van 18 AD patiënten met een 
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 acetylcholinesteraseremmer verhoogde de baroreflex gevoeligheid met 66%. 
Samengevat is de baroreflex verminderd in AD en neemt deze toe na behandeling 
met acetylcholinesterase remmers. De pathofysiologische en diagnostische 
betekenis van deze verminderde baroreflex in AD vergt nader onderzoek.
 Tenslotte wordt in hoofdstuk 6 de dynamische cerebrale autoregulatie en 
de hersenweefsel-oxygenatie in AD bestudeerd. Bij 21 patiënten met een milde 
tot matige AD en 20 leeftijd en geslacht gematchte controles, onderzochten we 
hoe oscillaties van de cerebrale bloeddoorstroming snelheid (CBFV) en hersen-
weefsel-oxygenatie (O2Hb) gerelateerd zijn aan oscillaties in bloeddruk 
geïnduceerd door herhaalde zit-sta manoeuvres met een frequentie van 0,05 Hz 
en 0,1 Hz. In AD was de cerebrovasculaire weerstand 34% hoger in vergelijking 
met de leeftijd gematchte controles. Ondanks een hogere cerebrovasculaire 
weerstand was er geen verschil in de dynamische autoregulatie tussen patiënten 
met AD en gezonde controles. Echter, bij patiënten met AD was de overdracht 
van CBFV naar O2Hb anders dan in de controle personen. De verhoogde 
 cerebrovasculaire weerstand en de veranderde overdracht van de cerebrale bloed - 
stroom naar de hersenweefsel-oxygenatie, zou kunnen wijzen op veranderde 
eigenschappen van de cerebrale microvasculatuur of een veranderd oxidatief 
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Marjolein van de Pol, bedankt voor onze intensieve prettige samenwerking op 
onderwijs gebied. Ik hoop dat nog lang met je te mogen doen. 
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de Biker, Peter Prosinecki (alias de witte Socrates, Kermit de probleemoplosser 
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woord besteed aan jou er één te veel). Over jou straks meer, Frans. Jongens 
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Mijn beste paranimfen, Frans Blom en Vincent Jaddoe. Lang geleden mocht ik 
paranimf bij jullie promotie zijn. Vandaag ben ik zeer verheugd dat ik dit jullie 
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vous embrasse très fort. 
Lieve Toine en Bert, bedankt voor jullie liefde en de velerlei steun op velerlei 
gebieden. Je hebt je ouders niet voor het uitkiezen, maar ik ben dankbaar dat 
jullie mijn ouders zijn. 
Lieve Marieke, wat bewaar ik en Valérie een dierbare herinneringen aan het 
verblijf bij jou in Zambia. Maar nu ook dichterbij huis bedankt voor het er zijn 
voor ons en de kinderen. Je bent een fantastische zus!
Lieve Célia en Florian, nos boubouns, mijn liefste lieverdjes, wat ben ik blij om 
jullie vader te zijn. Wat een genot om jullie te zien opgroeien. 
Lieve Valérie, la femme de ma vie. C’est fini! Het is tijd om nu eens echt Frans te 
leren. Alleen een stelling aan jou wijden zou je te kort doen. Bedankt voor je 
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